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The purpose of this research project was to evaluate 
the role of the community pharmacist in screening, 
identifying, and referring ambulatory patients with high 
total blood cholesterol (TBC) in a community pharmacy. 
Fifty seven patients, out of 241 initially screened 
individuals, met the study inclusion criteria and were 
accepted into this study. Of these 57 patients, 51 
patients completed the six month study period. The normal 
population group consisted of 164 participants with TBC < 
200 mgjdL at the initial cholesterol testing (visit 1). 
The drop out group represented six patients who failed to 
continue attending the two follow up tests (visit 2 and 3). 
For screening purposes, a non-fasting whole blood sample 
was used to measure TBC using the Boehringer Mannheim 
Reflotron analyzer. 
The project was evaluated based on mean TBC levels 
obtained during the initial screening and the two follow up 
tests, pre-test and post-test scores, behavior and 
lifestyle changes, and the number of patients who received 
a physician's order for lipid analysis as a result of 
initial screening results. In addition, influence of age 
and educational background on lowering TBC in visits 2 and 
3, patient acceptance of blood screening in a community 
pharmacy and willingness to pay for this service in the 
future were also determined. 
i 
To assess the level of significance among the means 
of the tested parameters, both parametric (one-way analysis 
of variance, Scheffe's post hoc test and two sample t-test) 
and non-parametric statistics (Mann-Whitney and chi-square 
test) were used at a probability level of less than 0.05. 
There was a significant difference in mean TBC levels 
between visit 1 and 2, and between visit 1 and 3 (P< 0.01). 
However, no statistically significant difference was found 
between visit 2 and 3 (P= 0.48). In addition, there was no 
significant difference in the incidence of high blood 
cholesterol in terms of gender or age difference at the 
initial screening. Further, mean TBC levels between males 
and females remained statistically insignificant during the 
two follow up tests. However, younger patients were able 
to lower their mean TBC level in visit 2 and 3 compared 
with older patients (P=< 0.031). The one-way analysis of 
variance results showed that there was no statistically 
significant difference in TBC changes during the three 
visits by subjects categorized by educational background 
levels. Patient's attitude toward the idea of blood test 
measurement in community pharmacies was positive. Ninety 
eight percent of the study group stated that they strongly 
liked such an idea, 92.16% expressed a willingness to pay 
an average of $4.55 (range $3 or less to $10), and all 
agreed that it was a convenient service for them. 
It was concluded that cholesterol screening in this 
ii 
community pharmacy was effective and acceptable, and may 
prove to be financially feasible when effectively planned 
and marketed. This service provides the community 
pharmacist with an opportunity to offer a unique patient-
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cardiovascular disease (CVD) is the major cause of 
death and disability in the United states. It accounts for 
• 1-3 more deaths than all forms of cancer comb~ned. Coronary 
heart disease (CHD) strikes about five million Americans 
and is the cause of 550,000 deaths in the United states 
yearly. 3•4 The direct and indirect cost of CVD and CHD has 
been estimated at $85.21 and $64.4 billion a year, 
respectively. 2 ' 6 It was postulated that lowering blood 
cholesterol would result in direct benefits from 
anticipated reductions in lifetime expenditures for medical 
care. Indirect benefits result from an expected extension 
of work-life secondary to reduction in morbidity and 
mortality. 5 
According to the updated statement of the .1970 Inter-
Society Commission for Heart Disease Resources, there has 
been a significant decline in CVD mortality (35-40%) that 
appears to be continuing to the present. This decline in 
CVD as well as the distinct reduction in CHD mortality has 
coincided with a more effective control of hypertension, 
cigarette smoking, and lower consumption of fat and 
cholesterol in the American diet. 5 It has been es.timated 
that 60% of such decline in CHD mortality was attributed to 
life style changes and 40% due to medical intervention. 7 
This association was attributed to environmental 
1 
2 
influences, since genetic characteristics of a population 
cannot change in a short time. Pathologic and experimental 
observations support such association both in animal and 
human studies. 
Broad scientific studies ascertained the association 
between elevated serum lipids, due to either hereditary 
andjor life style, and the development of atherosclerosis 
and associated CHD. Further, the linear relationship 
between plasma lipid concentration, especially cholesterol, 
and the severity of atherosclerosis is well 
established. 5•8- 13 The early atherosclerotic lesions can 
cause significant narrowing of the blood vessels. However, 
this is a slowly developing process and presents no 
clinical symptoms in most cases. It is not until a 
significant occlusion of the vessel, due to calcification 
and fibrosis, that a clinically active period can be 
observed. This lesion is usually common in the fifth or 
sixth decade of life. 14 Variation in patient 
susceptibility is wide and is dependent on the type and 
intensity of underlying risk factors and the duration of 
exposure to those risk factors. It is important to keep in 
mind that the clinical manifestations of coronary heart 
disease often strike without warning. It is quite possible 
that the first manifestation is an irreversible brain or 
myocardial infarction or even sudden death. Therefore, 
emphasis on primary prevention is of a great importance. 
---------
Hyperlipidemia 
Hyperlipidemia (HLP) is defined as an elevation of 
plasma lipids, namely, cholesterol, triglycerides, and 
phospholipids. Hyperlipoproteinemia is a disturbance of 
lipid transport that results from abnormalities in the 
h . d d . f 1 1. t . 10 15·19 synt es~s or egra at~on o p asma ~popro e~ns. • 
Diverse proportions of cholesterol ester and triglycerides 
act as a core for high molecular weight particles called 
lipoproteins. In order for these particles to travel in 
the circulatory system, a surface coat of phospholipids, 
which is polar in nature, is needed. In addition to 
3 
phospholipids, the polar coat contains small amounts of un-
esterified cholesterol. These components represent 
lipoprotein (LP) particles. The outer surface of LP 
particles contains specific proteins, called apoproteins, 
which have the ability to bind to specific enzymes or 
transport proteins on cell membranes. Therefore, these 
apoproteins are of great importance in directing the 
lipoprotein particles to their sites of metabolism. 10•15 
There are five different classes of LP that normally 
circulate in human blood. They differ in their density, 
particle size, electrophoretic mobility, core composition, 
and the apoproteins in their surfaces. 18•20 The five main 
types are chylomicron, very low density lipoprotein (VLDL), 
intermediate low density lipoprotein (IDL), low density 
lipoprotein (LDL), and high density lipoprotein (HDL). The 
biochemical and clinical features of these lipoproteins are 
4 
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1Adapted from Reference #18 and #21. 
2very low density lipoprotein. 
3Low density lipoprotein. 
4High density lipoprotein. 
5 
6 
In order to understand the etiologies of the lipid 
disorders, CHD, and approaches to their treatment, a brief 
review of lipid transport and metabolism is presented. 
Lipid Transport 
Two pathways are involved in the transportation of 
lipids in our circulatory system, namely, the exogenous and 
the endogenous pathways. 
a. Exogenous Pathway 
The exogenous pathway involves the largest amount of 
lipoprotein which transports more than 100 grams of 
triglycerides and about one gram of cholesterol per day. 
Exogenous fat and cholesterol are incorporated within 
intestinal epithelial cells into a large LP called 
chylomicron. These particles reach the general 
circulation through intestinal lymph channels where they 
are subsequently transported to the capillaries of adipose 
tissues and skeletal muscle. 15 Chylomicrons are then 
exposed to the enzyme lipoprotein lipase (LPL) which is 
activated by apoprotein CII located on their surfaces. As 
a result, free fatty acids and monoglycerides are liber-
ated in capillaries, where they reach adipocyte or muscle 
cells for subsequent oxidation or re-esterification to 
triglycerides. 
The remainder of the chylomicron dissociates from the 
capillary endothelium and reenters the circulation as a 
remnant particle (IDL) . These particles travel to the 
liver, where they are effectively taken up through binding 
7 
of apolipoprotein E to its specific receptors on the 
surface of the hepatocyte. The surface-bound remnants are 
then taken into the cell and then degraded within lysosomes 
d . t d d t . 15 22 23 by the process called receptor-me 1a e en ocy os1s. ' • 
In summary, the overall result of the chylomicron transport 
process is to deliver dietary triglycerides to adipose 
tissues and cholesterol to the liver. 
b. Endogenous Pathway 
Between meals, free fatty acids are usually released 
from adipose tissue and supplied to the liver where about 
80% are used for energy. The rest of the free fatty acids 
are incorporated into VLDL particles along with 
cholesterol, phospholipids, and apolipoprotein. The VLDL 
particles are then secreted into the circulation. 
Therefore, whereas chylomicron particles carry 
triglycerides of dietary origin, VLDL particles carry 
triglycerides of endogenous origin. These later 
triglycerides have been formed from excess fat stored in 
and mobilized from adipose tissue. The VLDL particles are 
then exposed to the same LPL enzyme where triglycerides are 
removed from its core leading to smaller and denser IDL 
particles. These newly formed particles are metabolized 
and removed from the circulation by two different 
mechanisms. First, they may be taken up by specific 
receptors on the surface of the liver. Second, 50% may be 
converted to LDL particles via hepatic triglyceride lipase 
enzyme. The result of these two mechanisms is a release of 
l • 
LDL particles with a very rich amount of cholesterol into 
the general circulation. These LDL particles transport 
cholesterol to peripheral cells that utilize cholesterol 
for cell membrane and hormonal synthesis. 
Since LDL particles contain 60-70% cholesterol, 
inefficient removal of LDL from the circulation can result 
8 
in high blood cholesterol levels. Therefore, the longer 
the circulation time of LDL particles, the more likely they 
are taken up by scavenger cells (macrophage) . The 
scavenger cells are then converted to cholesterol-laden 
foam cells. It has been postulated that these macrophage 
cells are involved in the initial formation of the 
atherosclerotic lesion. 11 •24 
In the presence of lecithin cholesterol 
acetyltransferase (LCAT), cholesterol from LDL particles is 
esterified to form HDL particles. These particles deliver 
the cholesterol ester to the liver where it is removed and 
degraded by bile acids. Bile acids are then secreted into 
the intestine to facilitate fat metabolism. Thus, it is 
claimed that people with high LDL levels are more likely to 
develop atherosclerotic lesions and subsequent CHD. On the 
other hand, people with high levels of HDL tend to have an 
enhanced ability to remove cholesterol from foam cells and, 
therefore, are at low risk of developing 
atherosclerosis. 11 •25 "27 
Phenotype Classification of Hyperlipidemia 
The hyperlipidemias were initially classified based on 
9 
their electrophoretic lipoprotein pattern first suggested 
by Fredrickson and Lee. 16•28 This classification has proved 
to be useful in classifying familial (primary) disorders or 
genetic abnormalities. However, it provides little 
information about the etiology of the lipid disorders and 
no information about altered concentrations of apoproteins 
or HDL or alteration in enzymatic activity. The American 
Heart Association in 1984 suggested a classification based 
on an etiology that would be more practical when evaluating 
the patient. This new classification system consists of 
three general categories that focus on the cause of 
hyperlipidemia. It entails secondary causes such as 
disorders in related metabolic systems, the use of certain 
medications, and abnormal dietary intake and lifestyle. 15 -
17,29 
Brown and Goldstein15 subdivided primary HLP into two 
major categories. The first category includes single-gene 
disorders which are transmitted by a simple recessive 
mechanism, while the second category includes a 
multifactorial disorder with complex inheritance patterns. 
It was stated that hyperlipidemias of type II, III, and IV 
are associated primarily with premature coronary artery 
disease, whereas profound hypertriglyceridemia of type I 
and V is often complicated by pancreatitis. 14 A summary of 
the major hyperlipoproteinemias and their phenotype-disease 
classification is presented in Table II. 10 
In contrast to the primary causes of HLP, the 
10 
Table II: 
Major Hyperlipidemias, Their Phenotype-Disease 





















































lAdapted from Reference #B and #18. 
2cholesterol. 
3Triglyceride. 
4coronary heart disease. 
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retinalis; mainly in 
adults. 
11 
secondary causes, including disease state, drug therapy, or 
lifestyle, are usually reversible if they were 
appropriately identified. In some cases, however, 
multifactorial inherited disorders might interact with 
environmental factors to produce a more serious form of 
lipid disorder. 8•15 
12 
Blood Cholesterol 
Cholesterol belongs to the class of compounds that is 
characterized by the basic steroidal carbon skeleton. It 
is a fat-like steroid alcohol with a structural formula 
C27H45oH. Cholesterol is found in animal fats and oils, in 
bile, blood, brain tissue, milk, egg yolk, myelin sheaths 
of nerve fiber, the liver, kidney, and adrenal glands. It 
is a precursor of bile acids and is an important component 
in the synthesis of steroidal hormones.• 
In spite of the fact that liver is the major site and 
source of cholesterol biosynthesis, nearly all body cells 
have the ability to synthesize cholesterol. Blood 
cholesterol circulates mainly in the form of LDL (65%), 
VLDL (15%), and HDL (20%). Hagan, et al., reported that 
movement from a 30 minute supine position to the standing 
position caused a 9.3 % increase in total cholesterol due 
to hemoconcentration. However, he stated that the TC/HDL 
ratio was not affected by such posture changes. 30 
The blood cholesterol level is a sum of both exogenous 
cholesterol and saturated fats from foods we eat and 
cholesterol that is endogenously generated by the liver. 
It is under restricted biochemical and enzymatic regulation 
including a sensitive feed back mechanism. This mechanism 
responds to both the blood cholesterol level and 
• Dorland's Illustrated Medical 
(Ed.). Twenty-Sixth Edition. 
Philadelphia. 1981; p.261. 
Dictionary. Friel J.P. 





lipoprotein receptor number, sensitivity and 
integrity. 10• 15 •22•31 Most circulating blood cholesterol is 
removed by converting it to bile acids in the liver. These 
bile acids are returned to the liver through the 
enterohepatic circulation.. The unabsorbed fraction is 
degraded in the large intestine and subsequently excreted 
in the feces. Blood cholesterol level is affected by the 
rate of lipoprotein synthesis and degradation. This 
process is affected by the presence of efficient or 
defective lipoprotein receptors both in hepatic and 
extrahepatic tissues. Therefore, a genetic defect in LDL 
receptors could result in a dramatic reduction of the LDL 
metabolic pathway (uptake) leading to hypercholes-
terolemia. 5• 10•22 In such a person, a build up of 
circulating LDL particles may occur in spite of eating a 
normal or low fat, low cholesterol diet. Presence of a 
high level of LDL and cholesterol in the blood, especially 
in the presence of local intimal lesions or hypertension, 
can lead to deposition of these particles in large and 
medium arteries. In addition, high blood cholesterol may 
suppress the synthesis of the hepatic LDL receptors. A slow 
but rather progressive build up of LDL with subsequent 
smooth muscle proliferation is .the key to the formation of 
atherosclerotic plaque. 2• 11,24,32 
An extensive body of scientific knowledge, including 
epidemiologic studies and animal studies, established 
beyond any reasonable doubt the causal relation between 
14 
elevated blood cholesterol and CHD. 2•5• 10• 12•20 •32 "34 Yusuf, et 
a1., 35 summarized the results of randomized clinical trials 
related to lowering blood cholesterol. He stated that " 
at least 22 randomized trials have evaluated reduction of 
cholesterol levels on a total of about 40,000 individuals." 
Some of these trials used drugs to lower cholesterol; in 
three other trials, dietary polyunsaturated fat was 
substituted for a saturated fat diet without changing the 
total fat intake. Nine studies were primary trials (where 
there was no evidence of CHD at the time of conducting the 
study) while the others were secondary trials. The author 
stated that the reduction in CHD was directly related to 
both the degree of lowering cholesterol levels and the 
duration of such reduction. 35 In the Framingham study, it 
has been estimated that a 10% reduction in blood 
cholesterol level is associated with a 10% reduction in CHD 
with treatment of less than four years duration. This 
effect on CHD is doubled (20% reduction) with more 
prolonged treatment. The risk of CHD begins to increase 
steeply in a curvilinear fashion above a cholesterol level 
of 200 mgjdL. It was estimated that this risk is fourfold 
in the top 10% as compared with the bottom 10% (Figure 
1). 12•20 •23 •32 In addition, Stamler, et al., documented that 
this relationship is not a threshold one and is not 
restricted to the highest quintiles, i.e., total blood 
cholesterol of 221-244 and 245 mgjdL or more, "but rather 
is a continuously graded one that powerfully affects 
18 
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Figure 1: Relationship of Serum Cholesterol to Coronary Heart 
Disease Death Rate in 361, 662 Men, Age 35 - 57 




risk for the great majority of middle-aged American men."9 
It was concluded, that reducing high cholesterol levels, 
particularly early in adult life and on a long term basis, 
can lead to a significant reduction in CHD. 35 
a. Effect of Dietary Cholesterol 
In a typical American diet, the average amount of 
cholesterol consumed is 450 mg daily. The human body 
synthesizes sufficient amounts of cholesterol to meet its 
daily needs. The relative importance of dietary saturated 
and polyunsaturated fatty acids and cholesterol in 
determining the blood cholesterol level has been a 
controversial issue. 36 Zanni, et al., reported a 
considerable inter-individual heterogeneity in response to 
diet. 37 However, as a general rule, ingestion of a diet 
high in saturated fats and cholesterol results in an 
elevation of serum cholesterol and increases the risk of 
CHD. 38 This increase in serum cholesterol was reported to 
be linear over the entire range of the amount of 
cholesterol ingested. A concomitant alteration in the 
amount of LDL and HDL particles and the cholesterol content 
per particle has been documented. 26 •37 It has been estimated 
that for each 100 mg cholesterol in 1000 Kcal of diet there 
is approximately 12 mgjdL increase in serum cholesterol. 36 
In an epidemiologic study, a low cholesterol level has 
been claimed to be associated with a higher incidence of 
cancer. However, it was explained that this is likely to 
17 
be due to 11 hypocholesterolemic effect of some cancer 
rather than the carcinogenic effect of lowering 
cholesterol level. "35 In a recent primary prevention 
study, it was confirmed that lowering elevated cholesterol 
has no influence on the cancer rate. 39 •40 Another concern 
was the occurrence of suicidal deaths in patients with low 
TBC. These concerns about cancer and suicidal deaths 
was based on studies of alcoholics and prisoners. 41 
McKenney addressed this issue and commented "No causal 
relationship has been demonstrated between lowering 
cholesterol and cancer, nor were there reports of increased 
cancer deaths in the two recent cholesterol lowering 
trials", i.e., LRC-CPPT and the Helsinki Heart study. The 
author added "Until lowering cholesterol has been shown to 
cause cancer, there is no justification for withholding 
cholesterol therapy on this basis. 1140 With advanced 
knowledge of the complex nature of lipid metabolism, and 
application of the latest techniques of cell biology and 
advanced research on lipoprotein receptors, it is now clear 
that dietary intake of saturated fat and cholesterol does 
in fact affect serum cholesterol levels and lipoprotein 
composition. 22 •26 •36-38 A cholesterol/saturated fat index 
(CSI) has been calculated based on a modification of the 
regression equation computed from metabolic studies. This 
score enables one to determine the relative 
hypercholesterolemic/atherogenic potential of a given food 
taking into account the food's content of saturated fat and 
;--
r 
cholesterol. It has been reported that the CSI per 1000 
Kcal correlates well with mortality from ischemic heart 
disease (r=0.78) in men 55-64 years old from 40 
countries. 42 
b. Seasonal Variation in Cholesterol Level 
several studies have conveyed the impression that 
cholesterol levels exhibit significant seasonal variation 
while others were unable to demonstrate significant 
variation. 4 •44-47 . Since serial and periodic cholesterol 
determination over several years has not been studied, 
these speculations need further investigation. In 
addition, some of the previous studies had limited 
statistical analysis of the results, and some based 
conclusions on results which were not statistically 
significant- 44 
The Lipid Research Clinics (LRC) Coronary Primary 
Prevention Trial (CPPT) is one well designed study that 
described such cyclic seasonal variation in cholesterol 
levels. A cohort of 1446 hypercholesterolemic 35 to 59-
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year-old men, initially free of CHD symptoms, were studied. 
This study used a uniform method for measuring blood 
cholesterol in the 12 LRC centers. All participants were 
maintained on a standard diet and were examined bimonthly 
for 7-10 years for cholesterol levels, body weight, and 
semiannual dietary assessment. 1•44 A highly significant 
seasonal effect in serum cholesterol level was found, with 
an average decrease of 7.4 mgjdL December 30 compared to 
that of June 30. 1•44"47 Such a trend in cholesterol 
variation was observed among the 12 LRC centers that 
include completely different climates. 45 Gordon, et al . , 
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pointed out that the magnitude of this seasonal variation 
was independent of baseline cholesterol levels as well as 
weight and saturated fat and cholesterol intake. Another 
study examined the effect of season on fasting plasma 
cholesterol in a group of 80 people seen during spring to 
autumn and another group of 73 subjects seen in summer and 
winter. In this study, no seasonal change in cholesterol 
levels was observed. 48 several factors were suggested as a 
possible cause of such seasonal variation. These may 
include diet, temperature, exercise, duration of daylight, 
and intrinsic and biological rhythm. However, the etiology 
and mechanisms for such seasonal patterns or the role of 
suggested causal factors remain to be answered. 45 •47 
This seasonal fluctuation in serum cholesterol is 
probably of minor importance in terms of the clinical 
management of hyperlipidemia. Serum cholesterol was 
reported to vary about 15 mgjdL from one visit to another 
and between different laboratories due to lack of 
standardization method between laboratories. Furthermore, 
a wide variety of parameters beside season of the year may 
affect serum cholesterol. Diet, temperature, and physical 
activity all are affected, in different ways, by season for 
different individuals. It is important, however, to take 
into account such trends in serum cholesterol and to be 
20 
aware of its possible existence when interpreting patient 
values. 
Secondary Hyperlipidemia 
A number of risk factors have been reported to be 
strongly associated with a high incidence of 
CHD. 2•5 • 10, 11 •32 •49 Among these factors elevated blood 
cholesterol, high blood pressure, and cigarette smoking are 
the most clearly established. 5•7•50"52 In fact, elevated 
serum cholesterol is a powerful independent risk factor for 
CHD. 49 •53 With the exception of familial HLP, the three well 
established risk factors are considered to be modifiable 
factors, i.e., under the patient's control. These are the 
areas suggested as the target in preventive medical care. 
Menotti, et al., 50 reported that these three risk factors 
apparently"· .. are of universal value within almost any 
population group or sample" based upon the 1984 report of 
Inter-society Commission. 
Secondary hyperlipidemia may not only be due to 
ingestion of high amounts of saturated fat and cholesterol 
but also could be due to a pre-existing disease state 
andjor as a side effect of the use of 
drugs. 5 • 10 • 15 •20 •21 •25 •34 •49 The most frequently reported forms of 
secondary hyperlipidemia were found to occur in association 
with cigarette smoking, diabetes mellitus, alcohol 
consumption, and ingestion of oral contraceptives. 
Additional disease states that might affect serum 
lipoprotein include Cushing's syndrome, hypothyroidism, I= 
I 
' ' [ 
[ 
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anorexia nervosa, uremia, nephrotic syndrome, primary 
biliary cirrhosis, acute hepatitis, lupus erythematosus, 
and monoclonal gammopathesis. Acute emotional stress, as 
in extensive burns, myocardial infarction, or gram negative 
sepsis, can also cause lipoprotein abnormalities. 10 •15 
a. Cigarette Smoking 
Cigarette smoking in the United States is reported to 
be responsible for about 30% of all deaths from CHD 
particularly in younger smokers. It has been reported that 
cigarette smokers have a 70% higher mortality from CHD 
compared to nonsmokers. This results in an estimated $19 
billion earning loss yearly. 5•10•51 Cigarette smoking is one 
of the major, graded, and independent factors for CHD. The 
risk is even higher in smokers who also have high blood 
pressure, elevated blood cholesterol, and in women who are 
using oral contraceptives. 5•51 •54 
Among the CHD risk factors, cigarette smoking is the 
most reported preventable cause of CHD deaths in both men 
and women. 10•51 The risk is proportional to the number of 
cigarettes smoked per day, not the number of years a person 
had been smoking. 4 •5•10•21 Smoking is also associated with 
substantial lowering of HDL level, although smokers who 
quit smoking for more than one year seem to have HDL levels 
equivalent to or slightly higher than those who had never 
smoked. 4 •10 •21 
Smokers were reported to be at a significantly higher 
risk of stroke, even after taking age and hypertension into 
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consideration. As with CHD, the risk of stroke increases 
as the number of cigarettes smoked increases. 55 •56 Cessation 
of cigarette smoking for two years reduces the risk of 
stroke, which was found to return back to the same level of 
nonsmokers five years after quitting smoking. 55 
Deanfield, et al., 54 examined the effect of smoking a 
single cigarette followed by exercise on regional 
myocardial perfusion in l3 chronic smokers with typical 
angina pectoris. Cigarette smoking was reported to be 
associated with a profound silent disturbance of regional 
myocardial perfusion and impaired coronary blood supply in 
response to exercise compared with the control (l6 healthy 
nonsmokers) . 54 
Cigarette smoking, in addition to predisposing the 
individual to lung cancer and emphysema, was reported to 
transiently increase platelet aggregation, increase heart 
rate and blood pressure, predispose the heart to 
ventricular fibrillation, decrease oxygen carrying capacity 
of hemoglobin, and raise fatty acid levels. 5•21 Therefore, 
smokers tend to have lower HDL, and are more susceptible to 
developing atherosclerosis and CHD particularly in female 
smokers. 
b. Oral Contraceptives 
Commercially available oral contraceptives contain 
variable amounts of estrogen andjor progestin, both of 
which seem to alter the lipid profile. 10•15 •57•58 It has been 
shown that plasma triglycerides and VLDL levels were higher 
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in a majority of oc users compared to nonusers. 6 •10• 15 
However, it seems that these two active ingredients have 
different effects on the LDL and HDL component of blood 
lipids and this difference appears to be dose-related. 
Preparations containing low amounts of estrogen and medium 
to high amounts of progestin appear to cause an increase in 
LDL and a decrease in HDL. On the other hand, 
administration of conjugated estrogens significantly 
increases HDL. 6•57•59 Premenopausal. women who used oral 
contraceptive products which are high in estrogen content 
but low in the amount of progestin had higher levels of 
HDL. In contrast, postmenopausal women who used estrogen 
had lower LDL concentrations compared to postmenopausal 
nonuser controls. 5•58 •59 
In women with a genetic disorder, plasma VLDL levels 
increase dramatically when estrogen containing medications 
were used. Therefore, it has been recommended that plasma 
cholesterol and triglyceride levels be measured before the 
institution of oral contraceptives. Documented findings of 
hyperlipidemia may be considered a contraindication to the 
use of these drugs. 15 
c. Alcohol Consumption 
Several studies have addressed the effects of moderate 
and severe alcohol intake on serum lipids and its 
association with coronary heart disease. 60-62 Ethyl alcohol 
consumption can produce a mild to severe elevation of VLDL 
fraction which appears to be dose related. 5•15 •61 Ethanol 
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elevates the plasma triglycerides through inhibition of 
fatty acid oxidation and by enhancing their hepatic 
synthesis. 15 Chronic ingestion of large amounts of alcohol 
may lead to pancreatitis, eruptive xanthomas, increased 
blood pressure, and lipemia retinalis, especially in 
patients with Type IV hyperlipidemia. 6• 15•62 It has been 
demonstrated that moderate alcohol ingestion can lead to a 
significant increase in HDL concentration and HD~ 
subtraction without affecting HDL mass. However, these 
changes were significantly decreased when ethyl alcohol was 
avoided. 60 It is important to point out that elevation of 
HDL2 subtraction and HDL appear to be negatively associated 
with CHD, while more dense HD~ subtraction is reportedly 
unrelated to CHD. 60 •63 •64 Moderate alcohol ingestion (30 
gramsjday) was found to be associated with a significant 
rise in HD~ and no change in HD~, whereas high dose.s (60 
gramsjday) were associated with a significant rise in HD~ 
and HD~ subtractions. 61 •63 The observed increase of HD~ 
and reduction of LDL levels in Taskinen's study61 as well 
as in animal models 63 was explained by an increase in 
lipoprotein lipase activity (LPL). Enhanced LPL activity 
will in turn increase both HD~ and HD~ subtraction only 
in chronic alcoholics but not in moderate alcoholics. In 
the animal model, lecithin cholesterol acetyltransferase 
was addressed to be the key enzyme that is affected by 
alcohol dose. The enzyme activity was increased with 
consumption of 12% calories from ethyl alcohol but 
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diminished and markedly lowered with consumption of l8% and 
24%, respectively.~ In a prospective study, moderate 
alcohol consumption in middle aged female nurses was 
associated with decreased risks of CHD and ischemic stroke 
but was reported to increase the risk of subarachnoid 
hemorrhage. 65 It appears that no single pathophysiologic 
mechanism can explain all alcohol-induced changes in serum 
lipids. Alcohol consumption especially in excessive 
amounts may increase the risk of hypertension, stroke, 
cancer, pancreatitis, and liver disease. The dangers of 
acute and chronic excess alcohol consumption far outweigh 
any possible or theoretical benefits from alcohol induced 
elevated HDL or lowered LDL. Therefore, alcohol should not 
be recommended as part of any health program in the 
prevention of CHD. 5 
d. Obesity and Physical Inactivity as Risk Factors 
In obese people, the liver tends to increase the rate 
of uptake of fats and carbohydrates from the intestine and 
to increase mobilization of fat from adipose tissue. This 
high load of free fatty acids may activate increased 
synthesis of VLDL, stimulate lipoprotein lipase activity, 
reduce HDL level and increase LDL level. 5•6 Although its 
contribution as an independent risk factor in CHD was not 
well established, obesity causes an alteration in many CHD 
risk factors. Obesity has been found to be highly 
associated with hypertension, glucose intolerance, and an 
abnormal lipid profile. Thus, extreme obesity (more than 
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30% over ideal body weight) is considered a risk factor and 
an important contributor to the risk of atherosclerosis and 
CHn. 5•21 •25 •51 •64 On the other hand, Leon, et al., showed 
supporting evidence of the hypothesis that CHD and overall 
mortality are inversely related to regular physical 
exertion even in people with a high risk for CHD.~ 
Regular exercise activity was proved to be useful in 
increasing the body's aerobic power, lowering heart rate 
and blood pressure, raising HDL concentration, reducing 
serum triglycerides, and decreasing body fat. 5•35 Although 
its beneficial impact on CHD appears to be less than those 
of the major risk factors, regular exercise is likely to be 
beneficial as part of a comprehensive risk reduction 
program. 5•35 
e. High Blood Pressure 
Elevated blood pressure is directly related to the risk 
of every major cardiovascular disease. It is more 
prevalent among blacks, elderly, obese, and oral 
contraceptive users. It has been reported that either 
elevated systolic or diastolic pressure increases the risk 
of CHD, although systolic pressure may be a better 
predictor. 5• 10 •21 •35 •67 High blood pressure has been found to 
be a more reliable CHD predictor than the level of 
cholesterol or cigarette smoking. 21 The Framingham study 
documented the poor correlation between blood cholesterol 
level and blood pressure (r=O.l2) . 67 However, a powerful 
interaction was found to exist between high blood pressure 
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and elevated blood cholesterol to produce CHD. The higher 
the blood pressure, the greater the probability of stroke 
and CHD. Serum cholesterol was found to be a strong and 
graded risk factor over its entire distribution from 182 
mgjdL and higher in men with high blood pressure. 10•68 
Further, it has been addressed that the risk of CHD 
mortality at least doubled in hypertensive males who smoke 
cigarettes. 68 Several techniques were suggested to control 
elevated blood pressure, including weight reduction, salt 
and caloric restriction, physical exercise, stress 
reduction, and selecting antihypertensive medications with 
minimal or no adverse effects on serum lipids. 51 •67 
f. Diabetes Mellitus 
Diabetes is a metabolic syndrome characterized by 
symptomatic glucose intolerance. It is more prevalent in 
females (2/3) than in males (1/3). Insulin-dependent 
diabetics represent about 5-10% of the 4-5 million diabetic 
population in the u.s .A. 18 Insulin is an important 
substance in blood glucose regulation. Low insulin level 
or lack of its secretion causes an increase in blood 
glucose due to decreased tissue utilization and increased 
fat mobilization from adipose tissue. As a result, a 
significant increase in VLDL and chylomicron synthesis and 
secretion in susceptible persons may occur. In some 
patients, there may be a slower rate of VLDL catabolism. 
Controlling blood sugar by either diet, weight loss, or 
drugs can reverse these abnormal lipid profiles. However, 
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a depressed HDL in patien"t:s w:i.::h non-insulin dependent 
diabetes mellitus may not be corrected by controlling blood 
glucose. 6 uncontrolled diabetes, on the other hand, has 
been found to be associated with vascular disease and 
,., 
increased risk of developing cno.'·· Hales with glucose 
intolerance have about a 50% higher chance of developing 
coronary artery disease (CAD) compared to males with no 
glucose intolerance. This effect varies widely based on 
glucose level and thP. coexistence of othe:;:- rislc factors. 
The lower the number of risk factors, the lower the risk of 
CHD. Diabetic females were reported to have double the 
risk of developing CAD than diabetic males, even when 
considering- the CAD rate differen=:e between males and 
females. It is important to remember that both 
hyperlipidemia and hyperglycemia tend to be associated with 
obesity and hypertension. 5•21 
Diabetics are more prone to a rapid progression of 
cardiovascular disease including hypertension, congestive 
heart failure, and CHD. 18 Atherosclerotic disease is still 
considered the major cause of death in 75% of all North 
American d:~.abetics. It has been postulated t.hat this high 
death rate is due to microvascular and neuropathic 
complications that lead to an extension of the 
atherosclerotic process and subsequent peripheral vascular 
disease; 5 • 18 These cardiovascular consequences of 
uncontrolled blood glucose may depend on the level of 
insulin, age of onset, etiology of the disease state, or 
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adequacy and efficacy of nutritional and drug therapy. 5 
g. Drug-Induced Hyperlipidemia 
Several studies have reported evidence of drug-induced 
hyperlipidemia. The most commonly reported drugs that may 
induce an abnormal lipid profile include: thiazide 
diuretics, beta blockers, nonsteroidal anti-estrogens, 
corticosteroids, oral contraceptives, and retinoic acid 
derivatives. 6 •10 •15 •16 Allopurinol and some benzodiazepines 
can significantly increase triglycerides. 32 Furthermore, 
many studies have documented the potential adverse effects 
of antihypertensive medication, in particular, on blood 
lipids. 69- 73 Thiazide diuretics were reported to 
consistently increase total blood cholesterol (TBC) levels 
by 4-13% and LDL by 7-29% compared to baseline levels. 
This phenomenon appears to be dose related. 6•71 Short term 
studies, however, have shown that the TBC/HDL ratio as well 
as HDL concentrations are often unchanged. 70 
Treatment with beta blockers, especially beta-1 and 
non-selective agents with no intrinsic sympathomimetic 
activity, also produce adverse effects on blood lipid 
profiles. This effect appears to worsen when these agents 
are used in combination with thiazide diuretics. 6 •70 In 
addition, methyldopa has been reported to decrease HDL by 
13-15%. 6 Among clinically used antihypertensive drugs, 
pindolol, acebutolol, labetolol, guanabenz, hydralazine, 
prazosin and calcium channel blocking agents appear to have 
few or no effects on serum lipids. 6 • 71 • 72 In contrast, 
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captopril in a dosage of 50 mg twice a day was found to be 
associated with beneficial effects on serum lipids. A 
significant reduction of 101 mgjdL in triglyceride level, 
50 mgjdL decrease in TBC, and 11% increase in HDL 
concentrations were noticed. Interestingly, these effects 
disappeared when captopril was discontinued, suggesting a 
cause-and-effect relationship.n It has been concluded 
that captopril has no significant harmful effects on serum 
lipids. 57 Isotretinoin and etretinate were reported to 
cause a significant increase in serum triglycerides and 
cholesterol resulting in eruptive xanthoma and 
pancreatitis. The exact mechanism of such severe 
lipoprotein changes is unknown, although VLDL and LDL 
. 6 73 
synthes~s enhancement has been proposed. ' 
It should be remembered that treating one factor is 
solving part of the CHD multifactorial problem. Therefore, 
screening for possible CHD risk factors and taking the 
steps to correct them may be considered the initial step in 
controlling CHD. 
Screening for Hyperlipidemia 
In order to initiate the steps toward controlling CHD, 
the general public needs to be informed about the 
significance of elevated blood cholesterol, its 
relationship with CHD, and methods of prevention and 
treatment available. Identifying individuals who need 
their cholesterol controlled is a crucial step toward the 
control of CHD. However, hyperlipidemia rarely produces 
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symptoms until late in life when angina pectoris, 
myocardial infarction, or heart attack could be the first 
and the only symptom.~ At this point, treatment may not 
restore the patient's original state of health but may halt 
further deterioration and progression or complication of 
coronary events. Therefore, as stated by McKenney 
" ... using symptoms to identify patients needing treatment 
is not wise ... ~ 
For a screening program to be justified, the 
following criteria must be met: 7 
l. The disease or condition must have a 
significant effect on the quality or quantity of 
life. 
2. Acceptable methods of treatment must be 
available. 
3. The condition must have an asymptomatic period 
during which detection and treatment significantly 
reduce morbidity or mortality. 
4. There are tests for this pre-symptomatic stage 
that are reliable and acceptable in terms of risk, 
cost, and degree of discomfort to the patients 
5. Treatment in the asymptomatic phase must yield 
therapeutic results superior to that obtained by 
delaying treatment until symptoms appear. 
6. Facilities are available for diagnosis and 





Until recently, establishing programs to screen 
cholesterol levels of large number of people was difficult 
to establish in a practical way due to the length of time 
and the high cost for each test. To correctly identify and 
subsequently treat individuals with high blood cholesterol, 
t d .. t t . d76 accura e an prec~se ~ns rumen s are requ~re . Now, 
there are at least three portable analyzers available 
whereby blood levels of different blood components can be 
measured from a finger stick blood sample.n The 
technological advantages of these portable analyzers, 
specifically those utilizing whole blood dry chemistry 
reagents, have made cholesterol screening for the public a 
reality. In such cases, blood cholesterol levels can be 
measured using approximately two drops of whole blood, and 
the test result can be obtained in less than three minutes. 
There was considerable variability between laboratories 
in terms of accuracy of cholesterol measurement. 10 •20 •78 ·79 
This situation restrained the national program intended to 
control heart disease. For this reason, the National 
Cholesterol Educational Program (NCEP) and its Laboratory 
Standardization Panel on Blood Cholesterol Measurement 
developed recommendations to improve laboratory 
performance. The following is a broad outline of the 
panel's recommendations that were addressed to improve the 
quality of cholesterol measurement:n 
1. Clinical laboratories in the United States 
should employ uniform cholesterol outpoints for 
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identifying adults at high risk for CHD. 
2. Laboratories must minimize method-specific bias 
and also achieve adequate precision of cholesterol 
measurement. This includes particular attention to 
method/instrument and calibration procedures. 
3. A deviation from the true cholesterol value of 
a standard sample (bias) should not exceed plus or 
minus 5% from the true value and should not be 
greater than plus or minus 3% from the true value 
within five years. 
4. All newly available portable chemistry 
analyzers for cholesterol measurement need further 
evaluation before they are adopted for routine use 
with patients. 
5. Proper training of technical personnel in the 
use, maintenance, and quality-assurance procedures 
are necessary. 
6. All clinical laboratories' measurements in the 
U.S.A. should and can be standardized so that their 
values are traceable to the Center of Disease 
control (CDC) reference method or to the National 
Bureau of Standards definitive method. This may be 
achieved by utilizing certified reference 
materials. 
7. To achieve adequate blood cholesterol 
measurements and to minimize the effect of 
interfering substances, modifications in reagents f 
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andjor instruments may be necessary. 
Serum cholesterol can be measured using an enzymatic 
method based on cholesterol esterase and oxidase reaction 
as in the case of the DuPont ACA and the Reflotron 
instruments or by the more economic colorimeteric assay. 10 
Several studies have recently evaluated precision, 
accuracy, and bias associated with the use of the new 
portable desk top analyzers used for measurement of 
TBC. 76 •77•80 •81 It has been concluded that the use of these 
instruments, when operated according to the manufacturer's 
recommended procedures, demonstrated acceptable accuracy 
and precision that met those goals established by the NCEP. 
The characteristics of the three most commonly used 
instruments for large cholesterol screening programs are 
presented in Table III. 77 
In spite of the inconclusive establishment of the 
proper age at which screening for hyperlipidemia (HLP) 
should be initiated, most screening tests are done after 
puberty. 49 It has been recommended that individuals with a 
family history of hypercholesterolemia and those with 
xamthomas, pancreatitis, or very premature CHD in first 
degree relatives be screened before puberty. On the other 
hand, those individuals with documented CHD in first degree 
relatives, women on oral contraceptives, most American men, 
and those with established risk factors should be screened 
between the age of 20 to 25. Lastly, everyone 20 years 





Accuracy study:l Cholesterol Testing of Three Office 
Chemistry Instruments Compared With LRC2 Results Using 
NCCLS 3 Guidelines for Method Comparisons. 
Y-Inter-
Instrument N Mean4 Slope cept r SE 5 Total 
mgjdL mg/dL mgjdL Bias % 
Abbott 83 223 l. 06 1 0.98 12 + 3.9 
Vision 
Boehringer 83 225 0.79 18 0.97 13 + 4.5 
Mannheim 
Reflotron 
Kodak 83 211 0.9 20 0.98 10 - 1.8 
Ektachem 
DT 80 
1Adapted from Reference #77, p.3446. 
2Lipid Research Clinic. 
3National Committee for Clinical Laboratory Standards. 
4LRc Mean equals 215 mgjdL. 
5standard Error. 
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every five years and more often if the patient is obese, 
smoker, hypertensive, or diabetic. 49 
36 
Albeit the intensive effort of the NCEP to encourage 
the public to know their cholesterol level, only 29-57% of 
adults have had their cholesterol checked nationwide. 39 In 
fact the month of April 1988 was denoted as "National Know 
Your Cholesterol Month" in recognition of the need for 
federal, state, and local activities to support cholesterol 
awareness. Health care providers are encouraged to take 
the initial steps to inform their patients of their 
cholesterol value and what it means. 39 
Special attention should be paid to four subgroups in 
which it is wise to monitor and treat HLP, even with no 
significant elevation in serum cholesterol. The first 
category includes post coronary bypass patients where 
angina and new vein graft occlusion reoccur in a 
predictable number of them. The second category consists 
of patients on chronic renal dialysis, where 
atherosclerosis is often markedly accelerated. The third 
category represents patients with Tangier disease, a rare 
disease where HDL is almost totally absent. The fourth 
category includes patients with moderate or severe elevated 
triglyceride levels, particularly in those with hereditary 
deficiency of lipoprotein lipase (Type I & V phenotype). 49 
What Lipoprotein Fraction Should Be Measured? 
For screening purposes, it has been recommended to 
measure total blood cholesterol (TBC} in a non-fasting 
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state. Many studies have shown that high levels of LDL and 
TBC are strong risk factors for atherosclerosis and 
CHD. 7•18 Although LDL is the actual target of cholesterol-
lowering efforts, TBC can be used instead during the 
initial screening tests. The use of TBC as a screening 
tool is more available, less expensive, and does not 
require the patient to fast for 10-12 hours before the 
test. Furthermore, it has been demonstrated that both 
fasting and non-fasting measurements of TBC are equally 
reliable. 4• 18•20 •75 •82•83 In addition, it has been reported that 
TBC is not altered by the cholesterol or triglyceride 
content of meals, and therefore, there is no reason to use 
any other measure of blood lipids initially. 7• 18•20 • 75 •82 
When screening individuals for elevated blood 
cholesterol, the objective is not simply to label or 
classify the patients but rather to take preventive 
measures early in the disease state. Advancing the time of 
diagnosis, through initial TBC screening and referral 
procedures, might have a desirable prognostic value. The 
effectiveness of such procedures can be enhanced if 
effective therapy could be started during the asymptomatic 
period.~ Therefore, it is advocated that screening tests 
may have the potential to advance the time of diagnosis 
since survival is measured from the time of diagnosis 
rather than the time of onset. Mully~ concludes that 
" .•. the survival of patients whose diseases are detectable 
by screening should be expected to be longer than that of 
patients who present symptomatically." In addition, 
patients at risk of CHD who spend more time in the 
asymptomatic period, are more likely to be identified by 
screening tests than are patients with more aggressive 
disease, added Mully. It is important, however, to note 
that screening results should not be considered as 
definitive diagnostic tools. 
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Several considerations must be made before labeling 
patients with either high, normal, or low blood 
cholesterol. Diagnostic evaluations based on the 
lipoprotein pattern rather than TBC level was suggested to 
enhance sensitivity and specificity. 14 Labeling 
individuals may produce its own morbidity and negative 
effect on health perception. Furthermore, labeling can 
also have a negative outcome on employability and 
insurability.~ Since the treatment of HLP, either by 
dietary means or drug therapy can be life-long, expensive 
and sometimes exposes the patient to potentially hazardous 
side effects, it has been recommended to accurately 
evaluate patients for underlying risks of developing CHD 
including assessment of life style and drug andjor disease 
state influence. 
In a study involving 8449 subjects intended to evaluate 
the efficacy of screening for dyslipoproteinemia (both 
hyper- and hypolipoproteinemia), it was found that more 
than 80% of all the hyperlipidemic participants had 
hyperlipoproteinemias. It was concluded that such lipid 
screening provided a lower proportion of false-positive 
than false-negative results. In addition, most 
participants (>98%) without hyperlipoproteinemia (true 
negative) were correctly identified. 14 
General Versus Selective Screening 
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Selective screening may not serve as a sufficient means 
of reducing the incidence of CHD. This may be true since a 
large proportion of individuals at risk would not be 
examined if assessment was restricted to a targeted 
population with preestablished selected screening criteria. 
In addition, testing the cholesterol level as part of any 
first attendance medical examination (case finding 
approach) has been recommended to be the usual approach. 20 
The overall goal of both the general screening and case 
finding approach is to recognize people with high levels of 
risk factors who require treatment. 53 It has been 
emphasized that"··· detection of increased risk implies a 







Treatment of Hyperlipidemia 
In spite of the extensive clinical data and 
epidemiologic evidence linking elevated blood cholesterol 
levels to CHD, some doubt and controversy remains about the 
strength of the causal relationship between the two 
parameters. 2•4•6 • 16•85 The National Institutes of Health (NIH) 
and the National Heart, Lung, and Blood Institute (NHLBI) 
assembled a consensus conference on lowering blood 
cholesterol to prevent heart disease held from December 10-
12, 1984. 2 This conference was initiated to investigate 
the link of increased CHD with increased blood cholesterol, 
and to resolve the questions related to when to treat high 
blood cholesterol, and what should be done to diagnose such 
levels. This consensus panel met after the results of the 
Coronary Primary Prevention Trial had shown that "lowering 
blood levels of cholesterol actually has reduced the risk 
of heart attacks". This panel represented experts in a 
variety of disciplines including; cardiology, 
epidemiology, biostatistics, and experts on diet and 
nutrition, preventive and primary care medicine. The 
expert panel's goal was to get a consensus position on 
important and crucial questions. Among the questions 
raised were the following: 2•20 •85 
1. Is there a causal relationship between blood 
cholesterol level and CHD? 
2. Will reduction of elevated blood cholesterol help 
prevent CHD? 
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3. How and when should dietary and drug therapy be 
started? And under what circumstances? 
4. What are the goals of treatment? 
After hearing a series of presentations and reviewing all 
clinical and epidemiological data, the 1984 panel concluded 
that: 
a. Elevated blood cholesterol is a major cause of CHD. 
b. Lowering high cholesterol level (especially LDL) would 
help, beyond any doubt, in reducing the risk of CHD. 
c. Everyone with a blood cholesterol level above the 75th 
percentile (at or above 240mg/dL) is recommended to be 
treated. 2•85 
d. Dietary change under the guidance of a physician, 
dietitian, or other health professional is the primary 
treatment for high cholesterol. If response to diet is 
not adequate, appropriate drug therapy should be added. 
e. Since blood cholesterol levels of most Americans are 
undesirably high, which in large part is due to a large 
dietary intake of saturated fat and cholesterol, all 
Americans two years and older were advised to reduce 
their total fatty intake from the current level of 40% 
to 30% of total calories. Further, it recommended 
reducing saturated fat to less than 10% and increase 
polyunsaturated fat by no more than 10% of total 
calories, and reducing dietary intake of cholesterol to 
250-300 mg or less daily. 
f. Special attention should be paid to identify and manage 
other underlying risk factors such as hypertension, 
cigarette smoking, diabetes, and obesity. It is 
important to point out that the NIH consensus panel 
guidelines2 used to classify patients with blood 
cholesterol levels at the 75th and 90th percentiles 
based on patient's specific age {See Table IV (A)). 
To establish a detailed set of new guidelines that 
provides practical advice for dealing with the adult 
patient's cholesterol problem, the National Cholesterol 
Education Program (NCEP) asked a panel of experts in 1987 
to develop new guidelines for detection and management of 
high blood cholesterol. 85 The panel, which included 
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experts representing a variety of disciplines and a wide 
range of expertise, worked for over a year to establish a 
consensus position on additional questions. Cleeman 
reported a list of these questions that included " ... how to 
go about detecting and evaluating high blood cholesterol, 
at which levels of cholesterol to initiate treatment, what 
the goals of treatment are, how to use dietary therapy, and 
how and when to use drug therapy in addition to diet. ,as 
This major panel carried out its work through three 
subcommittees, namely, (1) the subcommittee on prevalence, 
detection, diagnosis and evaluation; (2) the subcommittee 
on dietary treatment; and (3) the subcommittee on drug 
therapy. The report of the expert panel on blood 
cholesterol in adults was first published in January 1988, 
representing a true and highly collective agreement 
I 
Table IV (A}: 
NIH1 Guidelines on Total Blood Cholesterol2 (1984}. 
Assigned Risk of Coronary Heart Disease For 
Age Moderate Risk 
20-29 > 200 mgjdL 
30-39 > 220 mgjdL 
40 and over > 240 mgjdL 
1National Institutes of Health. 
2Adapted from Reference #2, p.2083. 











NCEP1 Guidelines Based On Total Blood Cholesterol2 (1987). 
Desirable Borderline-High High 
Blood Cholesterol Blood Cholesterol Blood Cholesterol 
< 200 mgjdL 200-239 mgjdL 240 mgjdL & Above 
1National Cholesterol Educational Program. 
2Adapted from Reference #20, p.37. 
't. 85 posl. l.on. The panel recommendation is applied to any 
person who is 20 years and older regardless of sex. 20 • 29•85 
These guidelines include the following characteristics: 
l. The cutoff point at which interventions should be 
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initiated is a total blood cholesterol of 200 mgjdL or 
higher. 
2. Total blood cholesterol is used for initial case 
finding (screening) and monitoring the progress of 
dietary therapy, while LDL is used thereafter to refine 
the assessment of CHD risks and for establishing the 
final diagnoses. 
3. The individual's overall risk of CHD must incorporate 
additional risk factors other than TBC level which 
influence the choice of cut points and goals of 
cholesterol targeted levels. 
4. Cut points and specific goals for drug therapy are 
established that protect from overuse of lipid lowering 
drugs to achieve a cholesterol level that could have 
been reached by diet alone. 19 The NCEP expert panel 
report includes additional information dealing with an 
educational effort directed to all health care 
professionals including physicians, pharmacists, and 
dieticians. Furthermore, an overview and summary of 
classification, prevalence, detection, and evaluation 
of elevated blood cholesterol, evidence and magnitude 
of the link between high cholesterol and CHD and a 
step-wise approach of dietary and therapeutic treatment 
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are also presented. 20 
For initial screening of blood cholesterol, a non 
fasting state is recommended by the expert panel. 
Individuals are to be classified into one of three classes 
based upon their cholesterol level {See Table IV (B)}. A 
cholesterol level below 200 mgjdL, regardless of age or 
sex, is considered "desirable or normal". Persons within 
this class are advised to repeat their cholesterol test 
within 5 years from the initial screening and be assessed 
for other CHD risk factors and be given dietary and risk 
reduction information. A borderline-high blood cholesterol 
is referred to as blood cholesterol level of 200-239 mgjdL 
that needs to be rechecked annually. Patients in this 
second category who do not have a history or evidence of 
heart disease and/or less than two risk factors should be 
advised to start a "step-1 11 diet. The goal of such dietary 
therapy is to minimize the consumption of saturated fat to 
less than 10%, cholesterol to less than 300 mgjdL, and 
increase the carbohydrate intake to 50-60% of total 
calories. Total blood cholesterol should be checked at 4-6 
weeks and at three months after starting the step-1 diet to 
assess dietary intervention. If dietary goals have not 
been achieved, lipoprotein analysis should be initiated to 
determine LDL level. If the LDL level is found to be 
normal (less than 130 mg/dL), the patient should be advised 
to maintain a prudent diet and reduce controllable risk 
factors such as elevated blood pressure, cigarette smoking, F 
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and high blood sugar. The patient is then advised to 
recheck his/her total blood cholesterol quarterly for the 
first year and twice yearly thereafter. 20 •24 There are two 
options for people who have borderline-high blood 
cholesterol who failed the step-1 diet. Hejshe may be 
referred to a registered dietician to either retry this 
step-1 diet or start the step-2 diet (See Table V), based 
on clinical and risk factor considerations. Cholesterol is 
then remeasured in 3-6 weeks and at 3 months. Patients at 
high risk of developing CHD, TBC of more than 240 mgjdL or 
borderline-high risk plus definite heart disease andjor two 
additional risk factors, including male sex, should have a 
lipoprotein analysis done. In addition, a complete family 
history and clinical evaluation including screening for 
secondary causes (drug andjor disease induced) of 
hyperlipidemia (HLP). 
If LDL level was found to be normal, TBC should be 
repeated every five years and dietary and risk reduction 
information should be provided. In contrast, if the 
patient was found to have a borderline-high LDL (130-159 
mgjdL) with no heart disease or less than two CHD risk 
factors, a step-1 diet and the subsequent algorithm 
outlined above should be initiated and TBC should be 
evaluated annually. On the other hand, if the patient was 
found to have high risk LDL (160 mgjdL or higher) or has 
definite heart disease andjor two risk factors, a complete 






Dietary Therapy of High Blood Cholesterol Level. 1 
Recommended Dietary Intake 
Nutrient Step-One Step-Two 
Total Fat < 30% of tc2 < 30% of tc 
Saturated < 10% of tc < 7% of tc 
Polyunsaturated Up to 10% of tc Up to 10% of tc 
Monounsaturated 10-15% of tc 10-15% of tc 
Cholesterol 300 mgjdL < 200 mgjdL 
Carbohydrate 50-60% of tc 50-60% of tc 
Protein 10-20% of tc 10-20% of tc 
Total Calories to achieve and maintain desirable weight 
1Adapted from Reference #20, p.46. 
2tc= Total calories. 
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patient's total blood cholesterol, LDL, coronary risk 
profile, clinical status, age and sex, initiating a 
selective hypolipidemic drug therapy should be considered. 
For patients with borderline-high risk who have 
definite CHD or two risk factors as well as high risk 
groups, the goal of therapy is to lower LDL to below 130 mg 
and 160 mgjdL, respectively. The two dietary steps 
recommended by the panel in their report are very similar 
to dietary modifications recommended by the American Heart 
Association. 20 These diets are designed as part of a 
population-based program to progressively reduce the intake 
of saturated fats and cholesterol and to eliminate excess 
calories (See Table IV) . 5•20 It has been emphasized that 
physicians should let their patients understand that the 
goal of dietary therapy is not a temporary diet, but rather 
a permanent change in their eating behavior. 20 A schematic 
approach of classification, evaluation, and step-wise 
treatment approach based on TBC and LDL levels is presented 












Desirable Blood Cholesterol 
Borderline-High Blood Cholesterol 
High Blood Cholesterol 
Recommended Follow-up 
Total Cholesterol <200 mg/dl 
Total Cholesterol 200·239 mg/dl 
WITHOUTdeflnlte CHD 
or two other CHD risk 
factors (one of which 
can be male sex) 
WITH definite CHD 
or two other CHD risk 
factors (one of which 
can be male sex) 
Total Cholesterol 2240 mg/dl 
Repeat within 5 years 
Dietary Information and 
recheck annually 
Lipoprotein analysis; 
further action based on 
LDL-cholesterol level 
Figure 2: Initial Classification and Recommended Followup Based 
on Total Cholesterol. (Adapted from Reference #20). 
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Do Lipoprotein Analysis: 
12 hour fast 
• Measure total cholesterol, HDL·cholesterol, and 
trlglycerldes 
Estimate LDL-cholesterol= 
total cholesterol - HDL·cholesterol - (triglycerldes/5) 










WITHOUT CHD or two other ~160 mg/dl 
risk factors 





WITHOUT CHD or two other ~190 mg/dl 
risk factors 








Figure 3: Classification and Treatment Decision Based on LDL-
Cholesterol (Adapted from Reference #20). 
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Dietary Fish and Fibers 
It has been observed epidemiologically that 
cardiovascular mortality in Greenland Eskimos and the 
Japanese is relatively lower than that of the Western 
industrialized world. 86 •87 This difference is believed to be 
related to the protective effects of their diet which 
consists mainly of fish and marine foods in general. It is 
well known that most marine foods contain large quantities 
of omega-3-fatty acids, namely, eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). Several reports pointed 
out the beneficial effect of omega-3-fatty acid consumption 
on cardiovascular disease. 6•20 •86 •87 These reports 
demonstrated that these fatty acids can decrease 
triglycerides and cause a small decrease (or sometimes 
increase) in LDL cholesterol with no effect on HDL. 88 
However, it has been reported that "No studies are 
available either comparing the effectiveness and safety of 
fish oil with other lipid-lowering drugs or showing that 
fish oil causes regression of atheromata or decreases the 
incidence of coronary heart disease. 1188 
several mechanisms have been proposed for the potential 
beneficial cardiovascular effects of fish oil. The 
following are the major mechanisms proposed: 
1. Reducing the hepatic VLDL and fatty acid synthesis. 
2. Increased VLDL elimination. 
3. Enhanced fecal steroid excretion. 
4. Interfering with platelet aggregation which plays a 
key role in thrombosis and promotion of arterial 
smooth muscle cell proliferation. 
5. Alteration of monocytes and neutrophil function, 
thereby prevent formation of fatty streaks and 
fibrous plaque formation. 
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6. Reduction in blood pressure in patients with mild 
hypertension. 
It is important to keep in mind that fish oil 
consumption, especially in large amounts, may cause 
bleeding due to decreased platelet aggregation and 
increased bleeding time and, therefore, should be used with 
caution, if at all, in patients on anticoagulants or those 
with an active bleeding condition. This seems to be in 
accord with what has been reported in that Eskimos have a 
twofold higher incidence of stroke than citizens of Western 
countries. 29 •87 In addition, ingestion of large amounts of 
certain fish oils may contain toxic amounts of vitamin A 
and D. Overall, however, fish in general is considered a 
useful substitute for meats (which are rich in saturated 
fats) and may be of value in lowering triglyceride and 
cholesterol levels with minimal harmful side effects. 
Dietary ingestion of approximately 15-25 gramjday of 
soluble fibers was reported to be associated with a 5-15 
mgjdL reduction in plasma cholesterol. 20 oat products and 
beans, which contain a beta-glycan gum, pectin, and 
psyllium (e.g., Metamucil) were found to possess similar 
effects on blood lipids. 20 •89•90 
In a double blind, placebo-controlled parallel study, 
the effect of Metamucil (which contains 79% psyllium 
hydrophilic mucilloid) was found to reduce total blood 
cholesterol (TBC) by 14.8%, LDL level by 20.2%, and the 
ratio of LDL/HDL by 14.8% compared to baseline values. 89 
This effect was seen in response to 3.4 grams of psyllium 
three times per day for eight weeks, after a two-week 
baseline period. Impressively, psyllium treatment had no 
significant effect on body weight, blood pressure, HDL, 
triglycerides, or blood glucose. 
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Short term effects of psyllium supplements was reported 
to lower TBC by about 16%, while long term effects of 
dietary fibers from oat and bean reduced blood cholesterol 
by more than 20% and this effect was reported to last for 
at least 2 years in hypercholesterolemic men. 91 In the 
Fagerberg study, 90 Metamucil was reported to possess a safe 
and long acting effect on fasting blood glucose and serum 
cholesterol. 
Although these clinical studies documented the 
hypoglycemic and hypolipidemic effects of soluble fibers (a 
20-30% reduction in TBC), the American Heart Association 
diet (which lowers TBC by 3-7%) does not include dietary 
fiber as an approach to lowering blood cholesterol. on the 
other hand, some experts still question dietary fiber 
usefulness as a therapeutic modality. 91 However, it has 
been reported that patient compliance with dietary fiber 
treatment was excellent with no observed clinically 
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important side effects. 
Drug treatment 
It is to be emphasized that treatment of HLP by dietary 
means remains the cornerstone in the management of patients 
with elevated lipids. Dietary therapy should be tried for 
at least six months, or for 12 months if indicated by a 
physician, before considering drug treatment. This is 
because drug treatment can be tedious, lifelong, involves 
cost to patients, and poses potentially hazardous side 
effects. Therefore, consequences of anti- hyperlipidemic 
medication should be considered before starting drug 
therapy. Characteristics of drugs used to treat high blood 
lipid are presented in Table VI. 24 The bile acid 
sequestrants (cholestyramine and colestipol) and nicotinic 
acid are considered the drugs of first choice in the 
management of hyperlipidemia. These two drug categories 
lower the risk of CHD in clinical trials as well as have 
established long-term safety. 20 If used in the recommended 
dose, a 15-30% reduction in LDL level is expected. These 
two categories require considerable patient education in 
terms of how to take the drug and what to do to reduce the 
risk of side effects to improve patient compliance. It has 
been reported that bile acid sequestrants are often 
associated with increased triglyceride levels (equal or 
more than 250 mg/dL) due to increased hepatic VLDL 
synthesis. Therefore, in patients with concurrent 





Characteristics of the Hypolipidemic Drugs.l 
Agent Effect on Reduced risk Long-term Maintaining X Lowering Daily 
(Brand Name) lipoprotein of CH02 safety ac:tlerence LOL3 dosage 
Chol es tyramine Oec5 LDL Yes Yes 
r (Quest ran) 15-30 12·16g 
R~ire 
considerable 
Colestipol Dec LDL Yes Yes pat lent 
(Colestid) education 15·30 15·30 9 
Nicotinic Acid Dec LDL, Yes Yes j (Nicotar) lnc6 HDL7 15-30 3·6 9 
Dec VLOL 8 
Lovastatin Dec LDL, Not Not 
(Mevacor) Inc HDL proven established 
I 
25-45 40-80 mg 
Gemfibrozi l Dec LDL, Yes Yes 
(Lopid) Inc HDL 5·15 
Relatively 
easy 
Clofibrate Dec VLDL, Not Not 
CAtromide-S) May Inc proven established No effect 
HOL on LDL 
Prlbucol Dec LOL, Not Not 
(Lorelco) Dec HDL proven established 1 0·15 
lAdapted from References 16, 24, 35, and 88. 
2coronary Heart Disease. 
3 Low density lipoprotein. 



















acid is the drug of first choice. 
The 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase 
inhibitor (HMG-Co A), lovastatin, is a new member of a 
class of drugs that has been classified as a second line 
for treatment of lipid disorders. They are effective in 
lowering LDL (25-45% reduction), increasing HDL with an 
excellent level of compliance. Since this drug category is 
relatively new, its effectiveness in preventing or 
reversing atherosclerosis and CHD as well as its long-term 
safety have not yet been established. 20 However, 
lovastatin (in 20 mg and 40 mg twice daily) in a 12-week 
study in 264 patients has been shown to be more effective 
in lowering LDL and TBC and better tolerated than 
cholestyramine (12 grams twice daily) . 92 
Gemfibrozil (Lopid) is a drug that belongs to the 
Fibric acid category which is effective in lowering plasma 
triglycerides and VLDL while increasing HDL. In a recent 
five year blind trial (the Helsinki Heart Study) , Lopid has 
been shown to decrease triglyceride and LDL levels and 
increase HDL in 4, 081 asymptomatic men. 83 •93 This study has 
proven the effectiveness of the drug in decreasing the 
number of myocardial infarctions (56 in Lopid group vs. 84 
in placebo group) and therefore, is associated with low 
incidence of CHD. 
Probucol (Lorelco) and clofibrate (Atromid-S) are 
primarily effective for lowering triglyceride levels. 
However, probucol may decrease HDL in addition to its 
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significant side effects. Clofibrate may increase LDL, 
decrease libido, and increase gallstone and tumor 
formation. Therefore, these two drugs are not yet approved 
by the Food and Drug Administration for routine use in 
lowering elevated blood cholesterol levels and are 
considered to be last resort drugs. 
Community-based Cholesterol Screening 
A community-based cholesterol education program should 
give high priority to the goal of detection and 
intervention. However, in the past, several barriers to 
this goal have existed. 94 These barriers include the 
necessity for venipuncture by trained personnel to obtain 
blood samples, the expense of laboratory tests, the delay 
between sample collection and receiving the test results, 
and the lack of standardization for cholesterol 
determination across clinical laboratories. Fortunately, 
new guidelines were recommended in 1987 and new cholesterol 
values were clearly established. Furthermore, patient 
education material and affordable and accurate portable 
equipment became available to facilitate community-based 
cholesterol screening programs. Nevertheless, with these 
more restricted guidelines, a majority of individuals would 
be expected to experience ·difficulties with adherence to 
these guidelines or goals.~ 
Two pilot community-based cholesterol determination 
studies utilized the portable Kodak analyzer (EKTACHEM-
DT60) where the blood sample was collected from a finger F 
5ll 
puncture. 94 •95 In the Lefebvre94 cholesterol screening and 
education campaign, 1439 participants were recruit.ed 
through extensive media coverage from March to April 1985. 
It was reported that nearly 60% of recruited individuals 
were found to have blood cholesterol levels that exceeded 
recommended goals (TBC < 200 mgjdL). A series of 
cholesterol Screening, Counseling and Referral Events 
(SCOREs) were conducted several times weekly during the two 
month campaign. Cholesterol screening events were 
conducted in 21 sites including several churches, shopping 
plazas, local businesses, local area drug and retail 
stores. Two months from the initial screening, three 
hundred ninety nine individuals (27.7%) individuals had not 
returned for the second cholesterol measurement. Nearly 
sixty percent (57.69%) of the remaining 1040 persons had 
successfully reduced their blood cholesterol by an average 
of 29.1 mgjdL. In contrast, 423 persons (40.67) had an 
increase in blood cholesterol and additional 17 persons 
(1.63%) had no changes. 
The second study was conducted in the New York 
metropolitan area and lasted five days. 95 At the end of 
the study period, 12,432 participants had been tested at 
six sites including five hospitals and a health education 
facility. Approximately half the population reported that 
they had their cholesterol checked previously. Three 
hundred participants from the original screening were 
contacted by a telephone survey. Eighty eight claimed that 
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they saw their physicians (29.3%), however 57% of them 
reported that their physician did not measure their 
cholesterol again to confirm the initial screening results. 
Unfortunately, 54% of respondents received no advice from 
their physicians, while 36% reported that dietary changes 
were recommended. Surprisingly, 71% of individuals with 
cholesterol levels between 221-260 mgjdL were advised to do 
nothing and not to worry. 95 This indicates the need for 
cholesterol education programs which must be directed not 
only to the public but also to physicians. Referrals for 
lipoprotein analysis and initiation of dietary or lipid-
lowering drug therapy would be a major problem if 
physicians are not taking the appropriate steps to bring 
their patients' blood cholesterol down to acceptable 
levels. 94 
Several studies demonstrated the possibility of 
implementing community screening programs that targeted 
toward motivating more people to become aware of their 
cholesterol levels. 96 Educational programs should be 
targeted toward providing those with high serum levels the 
necessary information to help lower their cholesterol. 
General dietary recommendation, food selection, and follow 
up protocols to assess patient response to dietary changes 





Scope Of The Study 
It was pointed out that the availability of accurate 
and portable blood cholesterol measurement equipment, that 
utilizes blood obtained from a finger stick, facilitates 
screening efforts, especially for pharmacists. 32 Several 
advantages were reported to be associated with such health 
care program at community pharmacies. First, pharmacies 
have a wide geographic distribution and are easily 
accessible. Second, pharmacists can provide professional 
information and provide educational materials that enhances 
the screening effort. Third, they can establish referral 
and monitoring programs for those patients with 
hyperlipidemia and counsel patients on side effects of 
drugs, if prescribed. This enhances the pharmacist's long-
term contribution in controlling high blood cholesterol and 
CHD morbidity. 
It has been reported that total blood cholesterol 
screening in a community pharmacy may be an important new 
opportunity in pharmacy practice. Providing such screening 
service offers pharmacists a unique opportunity to expand 
their patient-oriented clinical services which may prove to 
be a financially feasible public health activity. 29 •97"99 
Pharmacists can improve the public's awareness and 
understanding of the importance of lowering blood 
cholesterol. It remains to be determined if screening with 




This current research project was initiated to 
investigate the feasibility and outcomes of conducting a 
cholesterol screening program in a community pharmacy. It 
was targeted toward identifying individuals with elevated 
blood cholesterol levels and helping them control their 
levels. Follow up procedures, pre- and post-test survey, 
CHD risk factors assessment, and medication screening were 
considered as an integral part of the study. This project 
was also intended to evaluate the impact of this new 
patient oriented community service in terms of TBC level 
lowering and behavior changes. Acceptability of the 
project to the participants and willingness to pay for the 
proposed service if it were to be available in their 
community pharmacy was also evaluated. Long term follow up 
and referral service following the initial screening was 
investigated to determine its effectiveness. 
GOALS AND OBJECTIVES 
Goals: 
1. To develop a model for screening, detecting, 
and referring ambulatory patients with elevated 
blood cholesterol in a community pharmacy. 
2. To increase the patients' awareness and 
understanding of the value of lowering their blood 
cholesterol and its impact on the morbidity and 
mortality of coronary heart disease (CHD). 
3. To establish a follow up procedure for those 
patients at high risk of developing CHD. 
4. To identify patients with multiple risk factors 
and to encourage them to see their primary health 
care provider to establish the final diagnosis and 
adherence to treatment regimen, if indicated. 
5. To provide motivation for patients with high 
blood cholesterol to lower their levels below 200 
mgjdL. 
6. To assess patients' acceptance of the model, 
its convenience, and potential utilization of 
screening procedures in a community pharmacy. 
Objectives: 
1. To investigate the role of a community 
pharmacist in screening and follow up of ambulatory 




2. To define criteria for the selection of the 
patient population accepted in this study. 
3. To identify those patients with elevated blood 
cholesterol who require further evaluation, 
monitoring andjor treatment. 
4. To provide appropriate educational material for 
all participants screened and answers to their 
questions about cholesterol and other related 
issues particularly those at high risk of 
developing CHD. 
4. To determine the impact of this project on: 
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a. The patients' awareness of the problem. 
b. Lowering blood cholesterol during the follow up 
period. 
c. The degree of participants' acceptance of the 
idea of screening cholesterol level in a 
community pharmacy. 
d. Participants' attitude in terms of convenience 
and future utilization of such service if it 




This community pharmacy screening project was designed 
in an attempt to identify individuals with elevated blood 
cholesterol. Patients classified at moderate or high risk 
for developing CHD would be referred to their physicians 
for further evaluation and treatment. 
At the time of the initial screening, a brief personal 
and family history was collected to assess those patients 
with potential risk factors for developing CHD. These 
collected data were used to identify those patients who 
were in need of referral and monitoring services. 
Follow up blood cholesterol testing during the five 
month period allowed assessment of patients' serum 
cholesterol status and response to dietary and exercise 
changes. It also allowed the pharmacist to screen patients 
for potential drugs that could induce or exacerbate 
hyperlipidemia. Follow up visits served as an appropriate 
time to provide additional teaching and counseling. Test 
results at the initial screening without subsequent follow 
up testing might needlessly worry patients. Motivating 
those patients with multiple risk factors to see their 
physicians was emphasized as the determining step in 
controlling their high cholesterol level. 
The study protocol and the consent form (See Appendix 





Research. The project's screening procedures, patient 
interviews, referral service, and follow up testing were 
conducted in the Campus Pharmacy, University of the 
Pacific, Stockton, California. 
Identification of Patients 
a. Subiect Recruitment 
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Two hundred and forty-one persons, including University 
of the Pacific students, faculty, and employees were 
screened for high blood cholesterol (200 mgjdL or more). 
Subjects were recruited through two advertisements in the 
University newspaper (The Pacifican) and signs posted 
around the campus. 
For screening· purposes, total blood cholesterol (TBC) 
was measured in a non-fasting state. 
b. Inclusion Criteria 
Patients were admitted to the study if they met the 
following inclusion criteria: 
1. Participants must be between 18 and 60 years of 
age. 
2. Participants must not know their cholesterol 
level and have not been told by a physician that 
they have high cholesterol level. 
3. Patients must not be receiving cholesterol 
reducing· agents. 
4. Participants must not be dieting or exercising 
already to reduce cholesterol levels. 
5. Participants must be available for f-ollow-up 
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during the six month period of the study. 
6. Participants must be ambulatory. 
7. If female, participants must not be pregnant. 
8. Participants must not be involved in other 
concurrent studies. 
All participants with an initial TBC of < 200 mgjdL, 
the "Normal Group" were excluded from subsequent blood 
testing and were given educational materials on maintaining 
good eating habits and exercise level. They were advised 
to check their TBC within the next five years and to keep a 
record of their test results. Since blood sampling is an 
invasive procedure, a written informed consent form was 
provided to each participant. Two consent forms were used, 
the first was required by the University committee on Human 
Research and the second was a release of liability 
requested by Boehringer Mannheim Diagnostics. After 
explaining the scope of the project, procedures involved, 
and accompanying hazards that might occur, each participant 
was asked to read the provided consent form and sign it, A 
carbon copy was given to each participant with the TBC test 
result at the initial visit. All participants were advised 
that the initial TBC test as well as the two subsequent 
follow up tests, when applicable, were free of charge. No 
fees were paid for any individual to participate in this 
study. In addition, participants were advised that the 
University of the Pacific has no special program by which 
it provides compensation for medical treatment if injury 
f 
r 
occurs during biomedical or behavioral research. 
c. Patient Population 
One hundred sixty-four patients were found to have a 
normal TBC, i.e., less than 200 mgjdL at the initial 
screening (Visit #1). This group will be referred to as 
the "Normal Population". Out of the remaining 77 
participants, 20 persons did not meet the inclusion 
criteria and therefore were excluded from subsequent 
testing and follow up procedures. This second group will 
be referred to as the "Excluded Group". The remaining 
patients (N=57) were included in this study. One month 
after the initial cholesterol testing (Visit #2), six of 
the included patients were unavailable for the follow up 
testing. Those patients were considered drop outs. All 
the participants on visit #2 successfully completed the 
second follow up testing (Visit #3) and, therefore, the 
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total number in the "Drop Out Group" was six patients. The 
remaining 51 patients who completed the study from day one 
to the end of the study period will be referred as the 
"Study Group". 
Data Collection 
The following data were collected for the 241 
participants during the initial screening: 
1. Individual's name, sex, date of birth, weight, 
height, and telephone number. 
2. Name of participant's family physician. 
3. Smoking status and number of cigarettes consumed 
i ,-
per day. 
4. Oral contraceptive use (females only). 
5. High blood sugar. 
6. Blood pressure. 
7. Exercise level. 
B. Family history of heart problems. e.g., 
Hypertension, angina, or heart attack. 
9. Abnormal thyroid function. 
10. Educational level. 
11. Low fatjweight control diet. 
12. Name and number of medications used on a chronic 
basis. 
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13. Total number of risk factors (see list on page 73). 
14. Initial total blood cholesterol level. 
In addition, the following data were collected for the 
51 participants who completed the study (the study group) : 
1. Initial TBC level and the subsequent two follow up 
levels. 
2. Pre-test and post-test survey scores. 
3. Patient's dietary andjor behavior modification in 
visit #2 and #3 as a result of knowing his/her initial 
TBC level. 
4. Patient's attitude toward,the idea of blood 
screening tests in community pharmacies. 
5. Convenience and future utilization of such service 
if it were to be available in their neighborhood 
pharmacy. 
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6. Indication of patients' willingness to pay for this 
service and proposed fees. 
7. Number of patients who had seen their physicians to 
establish the final diagnosis. 
8. Number of patients who actually received a 
physician's order for lipid analysis as a result of the 
pharmacist's referral service. 
Participants were assured that any information that was 
obtained in connection with this study that could be 
identified with them would remain confidential and would be 
disclosed only with their permission. 
Selection of Instrument 
The Boehringer-Mannheim analyzer (REFLOTRON) was used 
to determine cholesterol levels of the participants in this 
study. All auxiliary instruments, devices, and supplies 
were provided through Boehringer Mannheim Company.• The 
Reflotron analyzer was chosen because of the following 
features: 
1. It utilizes dry chemistry reagent tabs (no need 
for blood dilution or centrifugation) . 
2. It requires only 30 uL (about 2 drops) of whole 
blood that can be obtained from a finger stick. 
3.· It gives relatively accurate and reproducible 
results (< 5% bias) in less than three minutes. 
4. It requires minimal training and operating 
"Boehringer Mannheim Diagnostics. 9115 Hague Road. 




5. It can detect blood cholesterol levels in the 
100-406 mgjdL range. 
Reflotron Operation Procedures 
Operating the Reflotron analyzer is simple and involves 
the following three steps based on the manufacturer's 
recommendation: 
1. Turn on the power switch and wait for the analyzer 
to warm up, the word 'READY' will be displayed. Insert a 
cholesterol calibration tab, which carries a programmed 
magnetic code, into the Reflotron and close flap. In a 
moment, a 'CHOLESTEROL PROGRAM' message is displayed on the 
LED screen. Open flap and remove the programmed tab in its 
original vial for next day use. This calibration procedure 
can be avoided by the use of individually prograruned 
reagent tab which is slightly more expensive than the 
uncoded tabs. 
2. Remove reagent tab (the uncoded tabs were used in 
this study for economic purposes) from vial and close vial. 
Remove the protective foil. Carefully draw blood sample 
into capillary tube, avoiding air bubbles. Dispense blood 
sample (30 uL) onto center of red mesh area of tab using a 
quick, smooth motion. Do not allow pipette tip or 
capillary tube to touch the tab. 
3. Immediately insert tab with the reagent pad side up, 
until a click can be heard. When 'CLOSE DOOR' appears on 
the display, close the door. 
I 
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Test name abbreviation 'CHOL' and countdown from 175 
seconds to one will appear on the display. When time is 
up, test result will be displayed automatically, expressed 
in mgjdL. open door, remove tab. All materials that came 
in contact with blood, such as capillary tubes and lancets, 
were discarded in a biohazard container. 
Quality Control 
A. CHECK TABS: (Checking the optical system) 
Each week, a check test is performed to check the 
performance of the optical system of the Reflotron. The 
manufacturer's recommended test procedures are as follows: 
1. Switch on the Reflotron. Take a new check strip out 
of vial and close vial immediately. 
2. With no blood sample applied, insert the check strip 
into the instrument and close flap. 
3. The display 'CHECK' confirms that the coded data 
have been correctly read into the instrument. In about two 
minutes, a set of three-digit values shows on the display. 
4. Compare each of the three values with the 
corresponding reference value (mean) displayed on the vial 
label. If the three values displayed are within the 
specified confidence limits, the optical system is 
functioning properly. 
B. CONTROL SERA: (Checking the entire system) 
A universal sera (Precinorm U, Boehringer Mannheim 
Diagnostics) is used for checking the entire system. It 
consist of a freeze-dried control that is reconstituted by 
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dissolving the content of the vial in exactly two 
milliliters of redistilled water. Gently swirl vial for 30 
minutes, do not shake vial to avoid the formation of foam. 
1. Apply a control sera to a reagent tab using the 
Reflotron Eppendorf pipette, which uses disposable tips and 
insert the tab into the instrument. 
2. Compare the values displayed to control sera range 
printed on the package insert (usually 163-221 mgjdL) . If 
test value falls outside range, repeat test. 
Control sera should be stored at 4°C after being 
reconstituted. A new vial is recommended to be used every 
week. 
Initial Blood Cholesterol Screening 
During the initial total blood cholesterol (TBC) test 
(Visit 1), each participant was asked to read and sign two 
consent forms (Appendix A) before obtaining the blood 
sample. An alcohol swab was used to clean the 
participant's finger and excess al.cohol was gently wiped 
out using a 2X2 inch sterile pad. Surgical gloves were 
used during blood manipulation procedures to avoid direct 
blood contact. A finger stick was performed using an 
AUTOCLIXtm (Boehringer Mannheim Diagnostics) device that 
utilizes a. sterile lancet. The first drop of the 
participant's blood was discarded to ensure an 
uncontaminated sample. Thirty microliters of blood were 
collected in a small capillary tube which is internally 
coated with heparin lithium to guard aga.inst blood 
I 
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coagulation. The drawn blood sample was then analyzed 
using the standard testing procedures mentioned previously. 
Within three minutes, participant's TBC result in mgjdL was 
displayed on the screen. 
During the three minute waiting period each participant 
was asked to fill out a cholesterol data sheet (Appendix B) 
which include personal data and a health questionnaire 
intended to assess the patient's underlying CHD risk 
factors. Participants' exercise level was determined based 
on a 4-point scale ranging from zero (non-active) to three 
(active). Educational background or the number of years 
spent in learning was classified into five categories. 
Participants with the highest educational level 
(Postgraduate degree such as M.S. and Ph.D) were given a 
value of 5, whereas participants with the minimal degree of 
education (Grade School) were give a value of 1 (Appendix 
B) • 
Assessment of Risk Factors 
In order to assess the number of CHD risk factors the 
person might have, the following list of established risk 
factors was used in this project:• 
l. Male Sex. 
2. Hypertension. 
3. Diabetes Mellitus. 
4. Use of oral contraceptives. 





5. Severe obesity (> 30% overweight). 
6. Hypercholesterolemia (TBC > 200mgjdL). 
7. Family or personal history of heart attack 
8. Sedentary lifestyle (Physical inactivity). 
9. Cigarette smoking (10 or more cigarettes per 
day) 
10. Definite coronary heart disease, e.g., M.I. 
subclassification of Screened Population 
Subjects with an initial TBC of < 200 mgjdL were 
assured that they had a normal level and were given 
instructions to check their TBC in the next five years. 
They were also advised to follow a good and balanced diet 
and to maintain an ongoing exercise program. All 
participants were asked to fill out a pre-test survey which 
assessed their knowledge and 1.~nderstanding of high blood 
cholesterol and the consequences of untreated high levels 
(Appendix C). Each participant went home with a nutrition 
handout and brochures which provided up to date information 
about maintaining a normal cholesterol level and good 
dietary intake (Appendix D). A specially designed 
cholesterol screening wallet card was given to all 
participants with their TBC result recorded and dated 
(Appendix E) . 
Subjects with an initial TBC of 200 mgjdL or higher, 
who fulfilled the project's inclusion criteria, were 
invited to participate in the study. They were informed 
that two follow up TBC tests during the next five months 
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would be requested. To be eligible for such follow up 
testing, patients were asked to sign a preliminary 
evaluation sheet (Appendix F) . This signed evaluation 
sheet provided the authority for the project investigator 
to perform additional TBC testing, to refer patients to 
their family physicians or suitable health care center. In 
addition, it gave the investigator the legality to receive 
a copy of lipid analysis results performed at a standard 
laboratory for follow up purposes. 
Follow up Testing and Procedures 
Between the period of the initial screening and the 
first follow up test, patients with high TBC and additional 
risk factors were contacted by phone. This was intended to 
motivate them to see their physician for further 
evaluation. 
On the first follow up test (Visit 2), TBC was checked 
using the same testing procedures mentioned earlier. Test 
results were recorded in the patient's wallet card and any 
TBC difference from the first visit was calculated for each 
patient. Patients who demonstrated a decline in 
cholesterol level and those who did exercise and modified 
their dietary intake of fats and cholesterol were 
encouraged to continue doing so. However, patients for 
whom there was no improvement or slight increase in TBC 
were advised to take a more active role in controlling 
their TBC and to seek dietary council and medical 
intervention. Possible dietary changes and the value of 
I 
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initiating exercise program was again reinforced. This 
visit was an excellent opportunity to answer patients' 
questions concerning risk factors, dietary changes, TBC, 
and coronary heart diseases. 
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At the time of the second follow up test (Visit 3), 51 
patients had their TBC tested. They were provided with a 
list of eight blood tests available and were asked to 
circle the number of test(s) they would use in the future 
if these tests were to be available in their community 
pharmacy (Appendix G). They were also asked to answer a 
post-test survey that includes five repeated pre-test 
questions to assess any change in attitude and knowledge of 
cholesterol and its association with heart disease 
(Appendix H) , and to express their personal opinion and 
attitude toward the idea of blood screening in community 
pharmacies. Finally, a certificate of participation was 
awarded to all patients who completed the six month study 
in recognition of their efforts to lower their TBC and to 
reduce their chance of having coronary heart problems 
(Appendix I) . 
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Statistical Analysis" 
several methods of statistical analysis, both 
parametric and non-parametric, were used to detect the 
significance of differences among means of the tested 
parameters. All statistical methods in this study were 
applied at a probability level of less than 0.05. 
In order to compare results of certain parameters, the 
values obtained were coded first. The study group 
participants whose age was between 18-34 years of age were 
coded a value of one, whereas those 34-60 years old were 
coded a value of two. Similarly, total blood cholesterol 
(TBC) values were assigned a coded value of one (TBC of 
100-199 mgjdL) and to a value of two (TBC of 200-400 
mgjdL) . The following is a list of the statistical 
analysis methods used in this project: 
1. A one-way analysis of variance was used to 
determine the difference between the means of TBC levels in 
visit #1, #2, and #3 and used again to determine whether 
there was a significant difference between the four 
educational background levels. 
2. Scheffe's Post Hoc Test was used to compare 
differences between the mean TBC levels for statistically 
significant F-Test results. 
3. Student t-test was used to determine whether there 
• All statistical analyses were performed on the Fortune 
32:16 computer, using the Mini tab statistical program. 
Fortune System Corporation, Belmont, California. 
1982. 
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was a significant difference between two groups when 
applicable, while two sample t-test was used to compare the 
difference between two sets of data containing unequal 
patient numbers, e.g., the study group (N=51) versus the 
normal group (N=164). 
4. Two sample t-test was used to analyze coded data 
such as age, education background, sex, exercise levels, 
and difference in TBC results using the Reflotron analyzer 
against those obtained via standard laboratories. 
5. The non-parametric Mann-Whitney test was used as an 
alternative for the t-test for the difference between two 
independent samples (number of risk factors in the study 
group versus those of the normal population) assuming 
samples were drawn from an unequally distributed 
population. 
6. The correlation coefficient (r) was calculated for 
13 different parameters to estimate the level of 
correlation between examined parameters. 
7. Chi-square analysis was performed to compare sex 
distribution between the study group against the normal 
group. 
Total blood cholesterol results of the three visits 
along with pre-test, post-test results, and patients' 
demographic data are presented in the results section. 
RESULTS AND DISCUSSION 
The relationship between elevated blood cholesterol and 
increased risk of coronary heart disease (CHD) has been 
well documented during the past 10 years. There is now 
solid evidence demonstrating that a 1% decline in serum 
cholesterol results in a 2% reduction in risk of 
CHD. 4•2•5•32 The National Cholesterol Educational Program 
(NCEP) was initiated in November 1985 to contribute to 
lowering morbidity and mortality from CHD by lowering 
cholesterol in those who are at risk. The NCEP program's 
main goal was to motivate all adult Americans to know their 
cholesterol level by attending cholesterol screening 
programs and to ask their physicians to have their 
cholesterol tested. However, less than half the adult 
population (29-57%, Median 47%) have had their cholesterol 
tested, according to the 1987 Behavior Risk Factor 
Surveillance System from 33 states. 90 In addition, only 6% 
of adults surveyed were able to provide a value for their 
cholesterol level (range 1-19%). This was attributed at 
least in part to the problem of accessibility to and/or the 
high cost for cholesterol test. 
Now, with the availability of whole blood dry chemistry 
analyzers, a non-expensive total blood cholesterol. (TBC) 
test can be performed in less than five minutes in a non-
fasting state. Although the goal of dietary or drug 




on the basis of their TBC which serves as an indirect test 
of LDL. Measuring TBC has the advantage of low cost, the 
use of non-fasting blood specimens involved in the 
measurement, and the minimal amount of blood (two drops) 
required. A strong demand for establishing cholesterol 
screening programs was addressed as an effort to encourage 
more people to know their cholesterol level and what it 
means. 
This research project was conducted to investigate a 
cholesterol screening and referral service in a community 
pharmacy. It was theorized that an easily accessible 
community pharmacist could identify those patients at risk 
of CHD through blood cholesterol measurement and from both 
personal and family data. This research project, in 
contrast to any other published study, was also designed to 
evaluate the impact of such proposed service on patient 
outcomes in terms of blood cholesterol lowering during a 
six month period, changes in behavior, referral to 
physician and patient acceptance of the service. The 
project was not intended to evaluate its impact on 
morbidity or mortality because of the limited study period. 
The project's flow chart and time line is depicted in 
Figure 4. 
During the initial screening period (Visit #1}, a total 
of 241 participants were screened for elevated total blood 
cholesterol (TBC) in a non-fasting state. It is important 
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vary considerably between studies depending on several 
factors. These may include the number of screening sites 
involved in each screening program, the nature and the goal 
of such program, proposed or required fees for providing 
such service, method of follow up if any, and the length of 
the research study or screening program. 
Ninety three participants out of the initial 241 stated 
that they had their blood cholesterol checked (38.58%), 
which is less than but close to the 1987 estimate of 47% 
(29-57%). 
During the initial screening, one hundred sixty four 
participants were found to have a desirable blood 
cholesterol level (< 200 mg/dL) regardless of their age or 
sex. Selected demographic and statistical data for this 
"Normal Group" are presented in Table VII. All 
participants in this group were provided with general 
dietary and risk factor educational material (Appendix D). 
They were also advised to repeat their cholesterol 
measurement within the next five years and to record their 
levels in the cholesterol progress wallet card provided 
(Appendix E) . 
In contrast, 77 participants (31.95%) were found to 
have TBC > 200 mgjdL who had not been told previously that 
they had elevated cholesterol. This might have been due to 
the fact that their levels were considered to be normal 
based upon the 1984 guidelines. Surprisingly, 39 persons 




Selected Characteristics of Normal Population 
(Total Blood Cholesterol < 200 mgjdL) • 
Parameter 
Total Number Screened 
Average TBc1 (Range) 
Average Age (Range) 
sex (Males:Females) 
Family History of 
Heart Problems (%) 
Family History of 
Heart Attack (%) 
Average Number of 
Risk Factors (Range) 
Value 
164 
163.8 ( 100-199) 
29.97 (19-63) 
84:80 
83 (53.66 %) 
44 (26.83 %) 
1.35 (0-3) 
1TBC= Total blood cholesterol. 
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cholesterol levels had not had their cholesterol checked 
(against a reported 25.57% that was estimated from pooled 
results from 13,000 subjects).% In another five day 
screening study involving over 12,432 persons, it was 
reported that approximately 50% of these people never had 
their cholesterol level tested although 28% of them were 
found to be at moderate to high risk for CHD.n 
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According to the pre-established inclusion criteria, 57 
participants out of the 77 persons with TBC of 200 mgjdL or 
over were accepted in the study (74.03%). The remaining 20 
participants (25.97%) were excluded from further blood 
cholesterol testing and follow up procedures. Selected 
characteristics of these excluded persons are presented in 
Table VIII. One participant was excluded because she was 
pregnant (first trimester). It has been reported that 
pregnancy could lead to false lipid results due to hormonal 
and body fluid changes and she was advised that lipid 
analysis be performed six to nine months after delivery. 
Another two persons were 61 years old who had their TBC 
checked before and were told that they had high levels, 
therefore, were excluded. The remaining 17 excluded 
persons had their cholesterol checked previously and were 
told that it was high, including one who stated that his 
father, who is a practicing physician, would treat him. 
The follow up procedure of this community pharmacy 
screening project consisted of telephone contact within 2-4 
weeks of Visit #1 (the initial screening) and written 
Table VIII: 
Selected Characteristics of Excluded Patients. 
# Code Age Sex # RF l rsc2 
01 RG 36 MALE 4 203 
02 cs 44 FEMALE 2 204 
03 BT 27 MALE 3 202 
04 CT 29 FEMALE 1 200 
05 IG 61 FEMALE 2 224 
06 MD 24 MALE 3 245 
07 KC 51 MALE 5 300 
08 GN 57 FEMALE 3 234 
09 JE 58 FEMALE 2 255 
10 MC 58 MALE 3 204 
11 sc 55 FEMALE 3 217 
12 GO 46 MALE 3 288 
13 CF 61 MALE 4 217 
14 SF 35 MALE 3 233 
15 cc 59 MALE 3 239 
16 RK 43 HALE 3 270 
17 OS 46 MALE 3 267 
18 HN 46 FEMALE 2 256 
19 HI 55 FEMALE 2 234 
20 RM 29 FEMALE 3 233 
1Number of ~isk factors. 
3Family history of heart problems. 
5educational background. 
FHx HP3 FHx HA4 Ed Bg5 Reasons for 
Exclusion 
YES YES 4 CHK!TH 6 
YES NO 2 CHK/TH 
YES YES 4 CHK/TH 
NO NO 4 PREGNANT 
YES NO 3 CHK/AGE 
YES NO 3 CHK/TH 
YES NO 4 CHK/TH 
YES NO 3 CHK/TH 
YES YES 3 CHK/TH 
NO NO 5 CHK/TH 
YES YES 2 CHK/TH 
YES YES 5 CHK/TH 
YES NO 2 CHK/AGE 
NO NO 4 CHK/TH 
YES YES 5 CHK/TH 
YES NO 5 CHK/TH 
YES YES 5 CHK/TH 
YES NO 1 CHK/TH 
YES NO 5 CHK/TH 
YES NO 4 CHK/TH 
2Total blood cholesterol. 
4Family history of heart attack. 
6checked before and told high. 
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communication between Visit #1 (first follow up) and Visit 
#3 (the end of study period). The purpose of such 
communication was to remind the participant to adhere to a 
healthy diet and to maintain their regular exercise level, 
especially those with high TBC level andjor those at high 
risk of CHD. one month after the initial screening (Visit 
#2 or the first follow up test), six patients (10.53%) out 
of the 57 accepted participants were unable to attend this 
first follow up test and thus were placed in the "Drop out 
Group". Table IX gives selected characteristics of this 
group. With the exception of one patient, all drop out 
patients left the state and therefore were unavailable for 
follow up (83.33%). Patient #5 showed no interest in the 
follow up testing and stated that she would see her 
physician to have a lipid analysis performed. 
The remaining 51 patients, The study Group, 
successfully continued the second follow up test (Visit #3) 
with no drop outs in spite of the two month gap between the 
two visits #2 and #3. This was thought as an initial 
indicator of the study group's interest and 
conscientiousness in knowing what might be the effect of 
dietary and/or behavior changes on their blood cholesterol 
levels. It is worth analyzing, at this point, the behavior 
of the study group in terms of their attending the second 
follow up with no drop out. It is possible to assume that 
these participants became more concerned and aware about 
their high cholesterol levels and therefore were willing to 
Table IX: 
Selected Characteristics of Drop-Out Patients. 
# Code Age sex # RF 1 TBC2 FHx HP3 FHx HA 4 Ed Bg5 
01 MM 19 Male 2 254 NO 
02 cc 24 Female 2 286 Yes 
03 SG 22 Male 3 209 Yes 
04 RM 45 Female 4 216 Yes 
05 BP 35 Female 3 212 Yes 
06 AN 34 Male 3 203 Yes 
lNumber of risk factors. 
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have more tests, in spite of the possible physical 
discomfort or inconvenience. It might also be a subjective 
measure of satisfaction with the project, because they 
could have chosen to not appear for the second test with no 
obligation. The comprehensive demographic and statistical 
data of the study group (51 patients) including their TBC 
on the three visits, personal and risk factors assessment 
data are presented in Tables X and XI. 
Table XII summarizes major descriptive statistical data 
for the study Group (N=51), the Normal Group (N=l64), and 
the Total Population Group (N=241). Since the study group 
patients were included in the overall total population, all 
performed statistical analysis were based upon the 
difference between this group and the normal population 
group only, unless otherwise indicated. 
General Comparative Analyses 
The mean total blood cholesterol of the normal group 
was found to be 163.80 mgjdL which, because of the 
inclusion criteria, is significantly lower than that of the 
study group at 225.69 mg/dL (P < 0.001). A histogram 
presenting the TBC distribution of the three groups is 
presented in Figure 5. As can be seen, the TBC 
distribution of the total population exhibits a bell-shaped 
curve which is a characteristic feature observed in most 
clinical and epidemiological studies including the 
Framingham study. The study group represents the right 
half of the curve with TBC of 200 mgjdL and above, while 
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Table x: 
study Group comprehensive Data. 
TBCI' TBC2' rsc3• \ Change' \ Change• .\ge Sex' 
230 17~ 182 23.9130 ~0.8696 21 1 
235 237 22~ -0.8511 4.6809 45 1 
222 235 211 -5.85~9 ~.9ssc; 39 1 
289 285 273 1 .38~1 5.5363 40 0 
228 217 216 4.8246 5.2632 27 1 
210 193 ISS a. o9s2 7 .!429 22 0 
219 227 237 -3.6530 -8.2192 52 0 
221 229 181 -3.6199 18.0995 28 1 
216 177 181 18.0556 16.2037 20 0 
252 227 219 9.9206 13.0952 4~ 1 
210 139 210 5.2381 o.oooo 52 0 
23~ 196 189 16.5957 19.57~~ 22 I 
202 202 211 o.oooo -4.4554 60 0 
251 221 266 11.9522 -5' 9761 48 I 
246 131 199 22.3577 19.1057 38 I 
208 213 247 -2.4038 ·18.7500 46 1 
207 172 206 16.9082 0.4831 23 0 
223 232 215 -4.0359 3.587~ 24 0 
20~ 203 204 0.4902 o.oooo 60 I 
223 197 208 11 '6592 6.7265 27 0 
216 209 16~ 3.2407 2~.0741 26 0 
231 168 180 27.2727 22.0779 2~ 1 
200 176 23<4 12o0000 ·17.0000 23 0 
2~1 231 214 4. 149~ I 1.2033 22 0 
238 171 240 28.1513 -0.8403 22 0 
210 169 157 19.5238 25.2381 22 0 I 256 198 194 22.6563 24.2188 24 0 
242 190 229 21.4876 5.3719 28 0 
206 197 199 4.3689 3.3981 27 I 
21~ 196 185 8.~112 13.5514 46 0 
217 201 192 7.3733 ,, 5207 58 0 
20~ 217 20~ -6.3725 o.oooo 22 I 
225 196 225 12.8889 o.oooo 23 0 
227 236 230 -3.9648 -1.3216 54 0 
222 211 146 4.9550 34.2342 29 I 
229 216 243 5.6769 -6.1 13~ 52 0 
257 227 236 II ,6732 8.1712 so 0 
21~ 229 216 -7.0093 -0.93~6 21 0 
21~ 203 157 s. 1402 . 26.6355 23 I 
284 236 281 16.9014 1.0563 56 0 
201 F9 199 10.9453 0.9950 29 1 
213 ~~ 184 13.6150 13.61~0 46 I 
201 198 180 1.4925 10.4478 48 0 
239 225 220 5.8577 7.9498 45 1 
209 193 179 7.6555 14.3541 40 1 
21~ 215 215 o.oooo o.oooo 43 0 
300 235 225 21.6667 25.0000 31 1 
208 174 191 16.3462 8.1731 52 I 
212 197 201 7.075~ 5.1887 ~5 0 
202 173 ~~ 14.35~ 3.4653 53 0 
232 157 178 32.3276 23.2759 21 0 
"Total blood cholesterol, Initial screening (Visit # 1) 
borotal blood cholesterol, Visit # 2 
<Total blood cholesterol, Visit # 3 
d% Change = (a - b) X 100 
e% Change = (a - c) X 100 
11 = Male ; 0 = Female 
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Table X: 
study Group comprehensive Data. {Continued) 
Ed- Bg< Ex-Lv• I RfC Pre-- t• Post-t• VI-V2' 1'1-Vl• 1'2-Vl' 
3 2 3 10 10 55 ~8 ·7 
5 0 5 10 10 -2 11 13 
4 1 3 10 10 ·13 II 24 
3 0 5 10 10 4 IS 12 
4 I 3 10 10 II 12 I 
3 0 2 10 10 17 IS ·2 
3 I 3 10 10 -a ·IB -I 0 
3 I 3 10 10 -B 40 48 
3 2 10 10 39 35 ·4 
5 2 10 10 25 33 B 
2 I 1 8 10 I I 0 ·I I 
3 3 2 I 0 10 39 46 7 
4 2 I B 10 0 -9 -9 
~ 2 s 10 I 0 30 -IS -45 
2 . 0 4 10 10 55 47 ·B 
5 3 3 I 0 10 -5 -39 -34 
4 3 3 10 10 35 I -34 
3 I ~ 8 10 ·9 8 17 
5 3 2 10 10 1 0 -I 
4 2 3 10 10 26 15 -I I 
~ 3 2 10 I 0 7 52 ~~ 
3 I 3 10 10 63 51 -12 
4 2 I 10 10 24 -3~ ·58 
3 I 2 10 10 10 27 17 
3 2 2 10 10 S7 -2 -69 
3 2 1 10 10 41 53 12 
3 I 3 10 10 58 62 ~ 
2 3 4 10 10 52 13 -39 
3 I 2 10 10 9 7 -2 
3 2 .2 10 10 18 29 ' I 
5 I 2 10 10 16 25 9 
3 3 3 10 10 -13 0 13 
3 I 3 10 10 29 0 -29 
4 2 3 10 10 -9 -3 6 
4 2 3 10 10 , 76 65 
3 I I 10 10 13 -14 -27 
2 0 3 10 10 30 21 ·9 
3 0 3 10 10 -15 ·2 13 
3 3 3 I 0 10 II 57 46 
s I 2 8 10 48 3 -45 
3 2 3 10 10 22 2 -20 
5 2 2 10 10 29 29 0 
5 2 I 10 10 3 21 IS 
' 2 3 6 10 14 19 ~ 3 3 3 10 10 16 30 14 
3 I 2 10 10 0 0 0 
4 0 2 10 10 65 75 10 
2 2 3 10 10 34 17 -17 
4 I I 10 10 IS II -4 
3 2 I 10 10 29 7 -22 
3 3 4 I 0 10 75 54 -21 
8Educational background. 
bExercise level. 
<Number of risk factors. 
dPre-test score. 
"Post-test score. 
1Total blood cholesterol difference (visit 1 - visit 2) • 
9Total blood cholesterol difference (visit 1 - visit 3) • 
hTotal blood cholesterol difference (visit 2 - visit 3) • 
Table XI: 
Study Group Descriptive Statistics. 
N Mean Median STOEVg SEMEANh Min 
TBC1 8 51 225.69 221.00 22.47 3.15 200 
TBC2b 51 204.61 201.00 24.73 3.64 157 
TBC3c 51 207.20 206.00 28.48 3.99 146 
% Changed 51 9.04 7.66 9. 76 1.37 ·7.01 
% Changee 51 7.94 5.37 11.34 1.59 ·18.75 
Age 51 36.43 31.00 13.37 1.87 20 
Education 
background 51 3.51 3.00 0.93 0.13 2.0 
Exercise 
level 51 1.57 2.00 0.96 0.14 0.0 
# R.Fsf 51 2.61 3.00 1. 10 0.15 1. 0 
Pre-test 
score 51 09.77 10.00 0.76 0. 11 6.0 
Post-test 
score 51 10.00 10.00 0.00 0.00 10.0 
aTotal blood cholesterol, Visit # 1. 
bTotal blood cholesterol, Visit # 2. 
cTotal blood cholesterol, Visit # 3. 
d% Change = (a - b) X 100. 
e% Change = (a - c) X 100. 
fNumber of risk factors. 
gstandard Deviation. 
















comparison of Selected Descriptive Statistics of the 
Study, Normal, and Total Population Groups. 
M: F 1 
N Rat 1 o MEAN MEDIAN STDEV 2 
STUDY: 51 22:29 
1. TBC 4 225.69 221.00 22.47 
2. Age 3 6. 4 3 31 . 00 13.3 7 
3. R. F. 5 2. 61 3. 0 0 1 . 1 0 
NorMal: 164 84:80 
1 • TBC 163.80 167.00 23.30 
2. Age 29.97 25.00 9.46 
3. R. F. 1 • 3 5 1 . 0 0 0.80 
Population 241 120:121 
1 . TBC 184.34 181.00 38.78 
2. Age 32.66 28.00 11 . 6 2 
3. R. F. 1 . 77 2. 00 1. 0 7 
lsex distribution, Males:Females. 
2standard Deviation. 
3standard Error of the mean. 
4Total blood cholesterol. 
5Number of risk factors. 
SEMEAN 3 M l N MAX 
3 . 1 5 200 300 
1 . 64 20 60 
0 . 1 5 1 6 
1 • 82 1 0 0 199 
0.74 1 9 63 
0.06 0 3 
2.50 1 0 0 300 
0. 75 1 9 63 
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Histogram of Total Blood Cholesterol for the Normal 
Group, the Study Group, and the Total Population Group. 
Total Group 
left portion represents people with normal TBC of <200 
mg/dL. 
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As can be seen from Table XII, the study group patients 
tend to be significantly older compared to the normal group 
(means 36.43 and 29.97 years, respectively, P< 0.05). The 
median was found to be 31 for the study group, 25 for the 
normal group, and 28 for the total population. Examining 
Figure 6, it was decided to use 35 as the breakpoint to 
classify the study group into two subgroups, those.who are 
under the age of 35 and the older patients whose age is 35-
60 years old. 
The sex distribution in the three groups tends to be 
equal, although more females were found in the study and 
total population groups than males (F:M ratio is 29:22 and 
121:120 respectively). The normal population had less 
females than males (80:84) compared to the study group 
(29:22), although this difference is not statistically 
significant (calculated chi-square value =1.014, P> 0.05). 
This is a unique finding in this study because most 
clinical and epidemiological studies reported that coronary 
heart disease tends to occur 4-5 times more in males than 
in females. In fact, male sex, according the NCEP expert 
panel of 1987 and the Framingham study, is considered a 
risk factor for CHD. 
When comparing the study group risk factors to those of 
the normal population, it was found that study group 













20 -11:~-a~m rfrntl t=ztt1 :::1 z 
0 








20 25 30 35 40 45 50 55 60 20 25 30 35 40 45 50 55 60 65 
Study Group 
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CHD than those of the normal group (mean of 2.61 versus 
1.35, P< 0.01). Since there is a possible argument that 
the study group may not represent an equally distributed 
sample, a non-parametric analysis was performed using the 
Mann-Whitney U test which is a non-parametric alternative 
to the two sample t-test. The non-parametric analysis of 
the number of risk factors between study and normal groups 
was also found to be statistically significant (P< 0.01). 
To assess the potential effect of the other risk factors, 
elevated TBC was temporarily excluded as a risk factor in 
the study group and statistical analysis was then 
perfoL~ed. The difference between the study and the normal 
group was found to be no longer statistically significant 
(mean 1.61 versus 1.36 respectively, P= 0.12). This might 
confirm the association between elevated blood cholesterol 
as an independent factor for CHD. Table XIII summarizes 
statistical analysis results comparing the study group data 
against those data reported for the normal population 
group. 
Study Group Comprehensive Analysis 
The results reported in Table XI shows the mean 
reduction of TBC during the follow up visits (Visit 2 & 3). 
The maximum and minimum TBC levels were lowered from 200-
300 mgjdL initially at visit 1 to 157-286 mgjdL in visit 2 
a.nd were lowered further at the end of study period, with 
visit 3 down to 146-281 mgjdL. This represents a percent 
change of -7.01 to 32.33% (-15 to 75 mgjdL) in visit 2 and 
Table XIII: 
Statistical Comparison of the Study Group 
Versus the Normal Population Group. 
Parameter N Mean 
TBC1 
-study 51 225.7 
-Normal 164 163.8 
Age (years) 
-study 51 36.40 






-study 51 2.61 




-Study 51 1.61 
-Normal 164 1.35 
1Total blood cholesterol, mgjdL. 
















and a -18.75 to 34.23% (-39 to 76 mgjdL) in visit 3. Forty 
four patients (86.27%) in visit 2 and 35 patients in visit 
3 of the study group stated that they changed their diet 
and/or improved their exercise as a result of the 
pharmacist's initial screening. Furthermore, 25 patients 
in visit 2 (49.02 %) and 22 patients in visit 3 (43.14%) 
showed a lowering in TBC level below the desirable 200 
mg/dL cutoff point. In addition, 40 patients (78.43%) in 
visit 2 and 37 patients (72.55%) in visit 3 demonstrated a 
lowering in TBC below their baseline levels in visit 1 
(Table X and Figure 7). On the other hand, only eight 
patients (15.69%) in visit 2 and nine patients (17.65%) in 
visit 3 had an increase in their TBC levels. It has been 
suggested that an expected 30-40 mgjdL reduction in TBC can 
be achieved over time by switching from the typical 
American diet to the step-one diet. An additional 15 mg/dL 
could be achieved by adhering to cholesterol-lowering diet 
as the patient advances to the step-two diet. 20 
The One-Way Analysis of Variance of the TBC on these 
three visits showed a statistically significant difference 
among the three groups, P< 0.01 (Table XIV). The Scheffe's 
test result showed a highly significant difference in mean 
TBC between visit 1 and 2 and between visit 1 and 3, P< 
0.01. In contrast, no significant difference was found 
between mean TBC levels in visit 2 and 3, P> 0.05. This 
indicates that patients in the study group were able to 
lower their mean TBC within a one month period and 
o; 
o; 
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Figure 7: Histogram of the Study Group Total Blood Cholesterol (TBC) Difference 
Between (Visit #1 - Visit #2) and Between (Visit #1 -Visit #3) 
Table XIV: 
One-Way Analysis of Variance of Total 
Blood Cholesterol in the Three Visits.a 
Mean total Blood Cholesterol 
( mg/dL ) 
Visit 1 225.69 
Visit 2 204.61 




ascheffe Value: Significant difference between visit 
1 and 2 and between Visit 1 and 3, 
(P< 0.01). No significant difference 
between visit 2 and 3, (P> 0.05). 
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succeeded in keeping it at a significantly lower level 
compared to their mean initial cholesterol level. 
Additionally, this might emphasize the need for early 
follow up procedures to assure patient compliance with 
prescribed diet or drug treatment especially for long-term 
management of elevated blood cholesterol. 
Six patients on the first follow up test (visit 2), 
four at high risk and two at moderate risk of CHD, reported 
that they contacted their physician as a result of the 
initial screening to establish their diagnosis. In 
addition, two more patients at high risk and another 
patient at moderate risk reported that they had seen their 
physician during the time interval between visit 2 and 
visit 3. It is important to note here that standard 
laboratory lipid analyses had been ordered for these nine 
patients by their physicians. Table XV shows that 
hypercholesterolemia was confirmed in all patients (N=9) 
referred with the exception of one patient who successfully 
lowered her TBC below 200 mg/dL. This patient had reported 
standard laboratory TBC result of 181 mg/dL on April 
25,1988, v:hich was found to be 177 mgjdL in May 4, 1988 
using the project analyzer "Reflotron". 
There was a "very good" association between standard 
laboratory results compared to that performed in the 
community pharmacy project. The difference in both TBC 
reported (Table XV) in those nine patients was not 
statistically different from the results reported fort the 
I 
Table XV: 
Comparison of Two Reflotron Results Against 
Those Obtained at standard Laboratories.a 
study Results Reflotron Standard Labs. 
codes Confirmed 
TBCb (md/dL) Test date TBC (mg/dl) Test date 
04 Yes 289 ; 285 03!23; 05/02 252 04/03/88 
08 Yes 221 ; 229 03/23;06/02 235 06/21/88 
09 Yes 216 ; 177 03/29;05/04 181 04/25/88 
1 0 Yes 252 ; 227 03/30;05/03 251 04/20/88 
24 Yes 241 ; 231 04/08;05/10 214 06/16/88 
36 Yes 229 ; 216 04/18;05!19 272' 04/25/88 
37 Yes 257 ; 227 04/18;05/19 277' 04/20/88 
40 Yes 284 ; 236 04/19;05/25 277 04/26/88 
47 Yes 300 ; 235 04/25;06/17 275 06/03/88 
Additional Out of the Study Comparison Data:d 
Volunteer 1 188 04/12/88 189 04!12/88 
Number: 2 178 07/01/88 168 07/01/88 
3 160 04/21/88 177 02/11/87 
4 217 04/15/88 223 12/15/87 
5 230 09!16/88 240 09/16/88 
aNo statistical significant difference (P= 0.69 
and P= o . 21) . 
bTBC= Total blood cholesterol. 
cDelta Medical Laboratory. 







same nine patients by standard laboratories (means 254.3 
versus 248.2 mg/dL, P= 0.69 for TBC initial levels and 
229.2 versus 248.2, P= 0.21 during visit 2 and 3). 
Additionally, a group of five volunteers who had their 
total blood cholesterol measured at standard laboratories 
were tested in this community pharmacy project to compare 
the laboratories' results to that of the Reflotron. Again, 
the difference between these project's results and those of 
standard laboratories were found statistically 
insignificant (study group mean of 194.6 versus 199.4 for 
the standard laboratories, P= 0.81). This was found to be 
in accord with the reported accuracy and precision of the 
Reflotron analyzer. 76 • 77•80 •81 On the other hand, the presence 
of inter-laboratory variation in TBC measurement was 
confined to only one laboratory. This laboratory reported 
relatively high values compared to those obtained during 
the community pharmacy screening tests (patient #36 & #37 
in Table XV). This problem of variation of serum 
cholesterol determination from one laboratory to another 
has been addressed in the literature. 76 •79 For this reason 
the National Committee for Clinical Laboratory Standards 
(NCCLS) through its council has approved the National 
Bureau of Standards (NBS) definitive method and the center 
for Disease Control (CDC) reference method and their 
certified reference materials as the accuracy base for 
serum cholesterol measurement in the United states. The 
CDC in a special repore6 stated that "The utilization of 
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the National Reference system for cholesterol will assist 
the organized national effort to assure and monitor 
reliable cholesterol determination in the laboratories." 
Therefore, users need to know the limitation and the 
percent bias of the new simple-to-operate desk-top 
analyzers before adopting them for routine patient use. 
Data on the patients' educational background (which 
reflects the number of years of education) were collected 
to investigate its effect on patients' initial TBC and 
subsequent behavior changes and their effect on the final 
cholesterol levels. Educational background was assessed 
using a scale from 1 (Grade School) to 5 (Postgraduate 
degree) as can be seen in Appendix B. None of the study 
group patients had an educational background below high 
school level (level 2). The average educational background 
level of the study group was 3.51 (range 2-5), an education 
above the undergraduate level. Therefore, they would be 
expected to have a relatively high pre-test score and even 
higher post-score results. As expected, the pre-test score 
ranges from 60-100% while all post-score test were at 100%, 
a statistically significant difference at P< 0.05. 
To evaluate the influence of the number of years of 
education on final blood cholesterol, a One-Way Analysis of 
Variance was performed to compare TBC of the four 
educational levels in visit 2 and 3 to that at visit #1 
(initial screening test). As shown in Table XVI, the 
calculated F-values were 0.41, 0.98, and 1.34 for visit 1, 
105 
2, and 3 respectively, whereas F-table value was found to 
be 2.8. It is concluded that there was no statistically 
significant difference in terms of TBC changes during the 
three visits between the investigated four educational 
background levels. It is worth noting that patients in the 
four educational levels had successfully lowered their mean 
TBC levels in visit 2 and 3 compared to their initial mean 
levels. However, patients with high school level and the 
postgraduate degree patients did worse in visit 3 compared 
to visit 2, though still less than their initial mean 
levels. 
Investigating the role of sex in lowering TBC, a two 
sample t-test was performed comparing male versus female 
mean TBC levels at the three visits. It was found that 
there were no significant differences in mean TBC levels 
between males and females in visit 1, 2, or 3 (calculated 
T-values are 0.12, 0.21, 1.41 respectively; T-table 50, 
a1pha=0.05 is 1.65). Mean total blood cholesterol (TBC) of 
males decreased from 226.3 in visit 1 to 205.0 in visit 2 
and even lower at 201.0 at the end of the study period 
(visit 3) . On the other hand, mean TBC of females 
decreased from 225.5 mg/dL in visit 1 to 203.6 in visit 2, 
but increased again to 212.2 mgjdL in visit 3. It is 
documented that as people get older their TBC tends to 
increase to a certain degree. Therefore, we investigated 
the effect of age on TBC by assigning all study group 
patients 35 years of age and under to subgroup 1 and those 
Table XVI: 
One-Way Analysis of Variance of Effect of 
Educational Background on Blood Cholesterol. 
Education Background Levela 
Variable 
level2 level3 level4 levelS 
Visit 1 232.60 223.36 223.55 230.40 
Visit 2 196. 2 0 200.88 207.91 214.50 






aLevels 2, 3, 4, and 5 represent high school, 
undergraduate student, undergraduate degree, 
and postgraduate degree classes respectively. 








of 36-60 years old to subgroup 2. The study patients were 
also categorized to two subgroups based on their TBC by 
coding their TBC into either subgroup l=TBC of 100-199 
mg/dL and subgroup 2=TBC of 200-300 mgjdL. Using this 
coding system for TBC and age, there was no statistically 
significant difference between younger patients (<35 years 
old) and older patients (36-60 years old) in terms of TBC 
in visit 1 (mean of 224.8 and 226.6 mgjdL respectively, P= 
0.78). In contrast younger patients did significantly 
better in terms of lowering their initial TBC than older 
patients in visit #2 and maintained this difference to the 
end of the study period (means 197.1 Vs. 212.4, P= 0.025 in 
visit 2, and 197.5 Vs. 217.3 in visit 3). When the 
difference in mean TBC between (Visit 1 - Visit 2) and 
(visit 1 - visit 3) was compared in terms of age code, 
younger patients had significantly higher mean TBC 
differences in visit 2 and 3 compared to visit 1 (mean 
lower TBC is 27.7 Vs. 14.2 mgjdL between visit 1 and visit 
2, P< 0.05 and 27.3 Vs. 9.3 mgjdL between visit 1 and 3, P< 
0.05. This might indicate that younger people are 
relatively easier to motivate to lower their TBC and to 
change their lifestyle than older people. If this was 
assumed to be the case 1 it seems prudent to start screening 
adult individuals 20 years and older or perhaps earlier in 
the presence of strong family history of CHD. Early 
detection and management of elevated TBC and assessment of 
underlying risk factors may be of potential value in 
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halting or even reversing the process of fatty streak build 
up and the development of atherosclerosis and CHD. 
A correlation matrix of TBC for the three visits, 
difference and percent changes in TBC during these visits, 
study group age, education level, exercise level, number of 
risk factors, pre- and post-test scores, was performed. 
There was no strong correlation between any of these 
parameters (r > 0.90 or higher). However, several positive 
correlations were found between TBC in visit 1 and that of 
visit 2 and 3 and between visit 2 and 3 (r= .515, 0.510, 
and 0.537, respectively). In addition, positive 
correlations were found between age and TBC in visit 2 and 
3 (r= 0.29 and 0.36), number of risk factors and TBC in 
visit 1, 2, and 3 (r= 0.37, 0.32, and 0.26). On the other 
hand, exercise level of the study group patients was 
negatively correlated with TBC in the three visits, 
although the correlation was weak (r= -0.436, -0.451, and 
-0.316). It is important to note that although TBC and 
hypertension, for example, are both independent and strong 
predictor risk factors of CHD, their correlation 
coefficient was reported to be 0.12 indicating weak 
correlation. 10•13 •67 Nevertheless, it was found in the same 
Framingham study that the increase in blood pressure 
paralleled the increase in total blood cholesterol. Thus, 
in hypertensive individuals, blood cholesterol related to 
CHD risk was found to be strong and graded from level 182 





percentile. 9•~ Furthermore, it should be remembered that 
CHD is a multifactorial health problem and not a disease of 
a single etiology. No one risk factor for CHD is a 
rigorous determinant by itself because the risk associated 
with any single factor varies with the constellation of 
other existing factors. Accordingly, multiple intervention 
should be targeted to lower elevated blood cholesterol and 
blood pressure, decrease the number of cigarettes smoked, 
and control elevated blood sugar. Also, lowering fat and 
cholesterol consumption and maintaining ideal body weight, 
screening for secondary hyperlipidemia including 
medications that might affect blood cholesterol or blood 
pressure, and other outlined lifestyle modification all 
contribute to lowering the incidence of CHD morbidity and 
ultimate mortality. 
Table XVII lists the study group patients on chronic 
medication, the number of drugs and their therapeutic 
categories used per patient. Thirteen patients (25.49%) of 
the study group use medications on a chronic basis (mean 
usage of 1.85 drugsjperson). As expected, approximately 
85% of these patients are above the age of 40 years. In 
the 20 year old patient (#9), rheumatoid arthritis was 
incorrectly diagnosed and the patient reported at the end 
of the study period that she was no longer taking her 
medication in light of the new diagnosis. The other 23 
.year old patient is taking minocycline for treating acne, 
in addition to her birth control pills, indicating no 
Table XVII: 
Study Group Patients on Chronic Medications. 
Code Age TBC1a TBC2 TBC3 # of 
Meds 
04 40 289 285 273 3 
07 52 219 227 237 2 
09 20 216 177 181 1 
11 52 210 199 210 2 
13 60 202 202 211 2 
17 23 207 172 206 2 
19 60 204 203 204 1 
31 58 217 201 192 2 
36 52 229 216 243 2 
37 60 258 227 236 4 
40 56 284 236 281 1 
46 43 215 215 215 1 
49 45 12 197 201 1 
aTBC = Total blood cholesterol. 
bBcP = Birth control pills. 


















underlying severe disease condition. The effects of 
medications used by the rest of eleven patients on blood 
cholesterol level were explained on an individual basis and 





Attitude Toward the Feasibility and Future 
Implementation of Blood Screening in Community Pharmacies 
During the final cholesterol test (visit 3) all 
patients were asked to complete a questionnaire by circling 
the appropriate answer indicating agreement or disagreement 
with the statements. The subject's willingness to pay a 
reasonable fee for this service if it were available in 
their community pharmacy was also investigated. Suggested 
fee levels were provided to each patient, namely, $3 or 
less, $5, $10, and more than $10 (See questions 11-14, 
Appendix G). Ninety eight percent (50 of 51) of the 51 
study patients stated that they strongly liked the idea of 
screening blood cholesterol in community pharmacies. One 
person showed moderate acceptance of this idea. All study 
group subjects agreed that providing this proposed 
community service would be very convenient for them. Forty 
seven patients (92.16%) showed a willingness to pay for 
this service if it were available in a community pharmacy. 
Only four patients (7.84%) reported they were unwilling to 
pay for this service. When asked about the reason for not 
paying for the services, some stated that unless they have 
medical problems, or had a strong family or personal 
history of CHD, they would not have their blood level 
tested. In others, they suggested that University of the 
Pacific should pay for this service during the initial 
student enrollment or as an ongoing service as a part of 
the University Health Center services. For those who r 
c 
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showed a willingness to pay, an average of $4.55 was 
proposed as a reasonable fee to charge for this service 
(Range $3 to $10). Keeping in mind that this project was 
conducted in an academic environment, where most of 
project's participants are students, most participants 
circled $3 or less. Further, since this was an 
experimental service not covered by conventional health 
insurance, many would be reluctant to endorse it as a high 
cost service. However, with more widespread and effective 
marketing of this service, it may be financially feasible 
to provide it at low cost to the public. 
When subjects were asked to identify which of the eight 
available tests they would use in the future, cholesterol 
(98.0%) and triglycerides (62.7%) were the two most 
desirable tests. This might be the result of intensive 
media coverage of the CHD/cholesterol issue during the 
period of this research project. In fact, April 1988 was 
chosen as the "Know Your Cholesterol" month in an effort to 
motivate everyone to know hisjher cholesterol level. Table 
XVIII reports the number and percentage of patients who 
indicated interest in future utilization of blood tests if 
available. In a five-week study~, 443 subjects completed 
a pharmacy blood service questionnaire involving blood 
level list of nine blood tests. Cholesterol and potassium 
were reported to be the tests subjects showed most interest 
in their availability in a community pharmacy (72.7% and 




Subjects Interest in Future Blood 
Level Measurement in Community Pharmacy. 
Number 
Tests Available of % 
Subjects 
Cholesterol 50 98.0 
Triglycerides 32 62.7 
Hemoglobin 16 31.4 
Glucose 24 47.1 
Uric Acid 12 23.5 
Serum creatinine 16 31.4 
Blood Urea Nitrogen 12 54.9 
Liver Function Tests 19 37.3 
(GGT, SGOT, SGPT) 
f 
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to glucose and hemoglobin (49.9%). 
Table XIX shows the number of patients in the study 
group whose TBC increased during visit 2 and 3, and 
corresponding behavior changes. Nine out of the listed 13 
patients in visit 2, and 12 of the 13 patients in visit 3 
showed a matching result that corresponds to their behavior 
change. 
Table XIX: 
Behavior Changes Versus Increased Cholesterol 
at Visit 2 and Visit 3. 
Diet/Exercise Did rscb 
Visit Visit Visit Changes Decreased? 
Code8 Age 1 2 3 
v2< v3d V2 V3 
02 45 235 237 224 NO YES NO YES 
03 40 222 235 211 YES YES NO YES 
07 52 219 227 237 NO NO NO NO 
13 60 202 202 221 NO NO YES NO 
14 48 251 221 266 YES NO YES NO 
16 46 208 213 247 YES YES NO NO 
18 24 223 232 215 YES YES NO YES 
23 23 200 176 234 YES NO YES NO 
25 22 I . 238 171 240 YES NO YES NO 
32 22 204 217 204 NO YES NO YES 
34 54 227 236 230 NO NO NO NO 
36 52 229 216 243 YES NO YES NO 
38 21 214 229 216 NO NO NO NO 
acode number of patients in the study group 
whose cholesterol increased during Visit 2 
and Visit 3. 




SUMMARY AND CONCLUSION 
This research project was undertaken to investigate the 
feasibility of conducting a cholesterol screening program 
in a community pharmacy. It was targeted toward 
identifying individuals with high blood cholesterol levels 
and those at high risk of coronary heart disease (CHD). 
Since CHD is usually a silent and slowly progressive 
disease that presents no early clinical symptoms, it was 
theorized that early detection of those at risk could 
advance the time of their diagnosis and hence enhance their 
prognostic value. Early detection and management of 
patients with hypercholesterolemia and those at CHD risk 
through screening programs would help eliminate or control 
these risk factors by taking preventive measures early 
before progression of the disease. 
In the 51 patients of the study group, there was a 
statistically significant reduction in mean total blood 
cholesterol (TBC) levels in visit 2 and 3 compared with the 
initial mean level (P< 0.01). The mean percent changes in 
TBC between visit 1 and 2 was 9.04% (range -7.01 to 32.33%) 
and 7.94% (range -18.75 to 34.23%) between visit 1 and 3. 
Furthermore, 25 patients (49.02%) in visit 2 and 22 
patients (43.14%) in visit 3 had successfully reduced their 
TBC to the recommended level (less than 200 mgjdL). 
Compared with the mean baseline TBC level, 41 patients 





visit 2 and visit 3, respectively. The study group 
patients were found to have a significantly higher number 
of risk factors compared to those of normal population 
group, P< 0.01. The drop out rate was found to be 10.53% 
(six patients) throughout the six month study period (as 
compared with a drop out rate of 27.7% after two months in 
a multi-site screening program) . 94 No age, sex, or 
educational background differences in terms of mean TBC 
levels were found during the initial TBC testing. However, 
young patients (less than 35 years old) significantly 
lowered their mean TBC levels compared with older patients 
(35-60 years old), P< 0.05). No difference in mean TBC was 
found between male and female patients in visit 2 or 3 
although both males and females were able to lower their 
mean TBC levels in these two visits. Similarly, there was 
no significant difference between the investigated 
educational background levels in terms of mean TBC levels 
during the two follow up visits (visit 2 and 3). Analysis 
of patient attitudes toward the model showed a positive 
acceptance. 
It is concluded that cholesterol screening in this 
community pharmacy was effective, acceptable, and may prove 
to be financially feasible if effectively planned. The 
concept of cholesterol testing and follow up should be 
tested in other non-academic setting to validate the 
findings of this study. It is expected that younger 
individuals (20 years old and above), those at high risk of 
developing CHD, and patients on medication to lower TBC 




Cholesterol Screening Project 
'icu are baing asked it you vh:h to take part in a cholesterol 
screening project. Please read this consent form carefully and ask 
as many questions as you like before deciding whether you want to 
participate. If you decide to participate in this study, you will 
have a finger stick pgrfor;ed hy· a pharmaci$t in order to collect 
the necessary blood sample tor the test. F inqer sticks are 
accompanied by minor discomfort at the site of the finger puncture 
and may result in slight bruising at the site. Approximately three 
drops of blood will be collected. The time required for this 
procedure should be less than five minutes. If your cholesterol 
level is over 200, you will be requested to appear for two follow-
up visits. The screening test we will use may overestimate true 
levels. 
The benafit yoy gao expect trom this stydy is the knowledge O! your 
cholesterol level and whether or not you should racaiva !urther 
evaluation by your physician. Elevated blood cholesterol is known 
to be directly correlated with a high incidence o! coronary artery 
disease which, i! undatected and untreated, may lead to 
atherosclerosis and heart attack. The durotign gt your 
portieipoting in this study is the time required !or ringer stick, 
blood collection and analysis, and answering the awarene•• survey 
provided. 
At the time of this initial screening, yoy yill be giyen a gopy gt 
th• results for your recgrds and a copy will ba torvardad to your 
physician, unless.you indicate otherwise. any intgr;otign that is 
obtained in connection with this study and that can be identified 
with you yi' l rem-ain cgnfidential and will be disclosed only with 
your permission. The sponsor o! this project will receive 
sUJDmaries ot the study. Also, you will be required to complete 
forms regarding your health. 
I! you have any questions, please ask. I! you have any additional 
questions later, please contact your pharmacist osama Ibrahim M.s. 
at (209) 946-2440, your Campus Pharmacy manager Joel wagner 
Pharm·P· at (209) 946-241: or the projee~ coordinator Dr. Patrick 
catanio at (209) 946-2491. 
Your siqnatur•· indicates that you have read the information 
provided and have had your questions answered and have decided to 
participate. 
I, , freely give my consent to take part in 
this study. I vill receive a copy ot this consent form for future 
reference. I have been advised that the Unive~sity o! the Pacific 
has no special program by which it provides compensation o! medical 
treatment i! injury occurs during biomedical or behavioral 
research. 
Signature ot Participant Date 
Signature ot Investigator Date 
Your blood cholesterol reading is ______ mg;cll Date: I /1988 
Would you like a written screening result to be sent to your 





Appendix A (Cont.) 
Boehringer Mannheim Diagnostic Consent Form 
Cholesterol Screening Consent 
and Release Statement 
121 
I her&by ~ease Boehringer Mannheim Corporarion. othllf orvanizarions associated with this wunmg. parent and affiilattd 
companies. successors and assigns. at1d officert dtrectors and employees from any and all liat.t.w ansrng !rom or ri1 any 
way connocte<l with blood drawmg for my blood cholestarof measurement or from the data dem!<lthen!lrom. I undmtand 
thn 
I) The data denved from th~ test are to be considered pl!iiminary on~ and do not constitute ' diagnosis of 
irypl!ltholesterolemra. 
21 With my permisSion. screening sponso11 may elect to send the results of this test to a Ph!"<~" of my chOICe 11 my 
r&SlJI!1 suggest that I may be at mcreased nsk for hean diSease accon!mg to the Nauonal losntutes of Health 
guidalmas 
31 Boellnnger Mannh•m Corporation will also rece"e a copy of this complet!d form. mcludmg test results. lor resl!illt:h 
purp~s on~. 
4) The responsibility for initiating a follow-up u:ammauon to confirm high blc:1d cholesterol ar.d cbtarn adv1ce and 





9tt5 Hogut Rood. I-• ..... IN 46250 
Date _ 
Appendix B 
llJii nora:l.ty of the Pacif.ic; 
Sc:bool. of Pbanacy 
Cholesterol Sc:rHIIillg Prcjeel: 
CRoi.!S'rEROL DATA SHEET 
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Date: I I 1988 
!I..,.:,T"::="\"'"""~>"t':':=:"l""""-,:zr:rr--1I.ut) (Firs:) (Hid) 
Dau of birth: I I Sa:: M F 
Telephone 1111111ber: ( ) 
lleillht: " Weisht: 
Familr Phrsieian: 
Please, m....r the follovillg gueatioas: 
l, Do :rou -.ka? !lo_ !••- l!ov lllllllY eigarottes/day: ---
2. Ara yon takina Birth Cclltrol Pills? Yes_ !lo_ 
~. Ara you & ciiabetie (hish blood sugar)? Yes_ !lo_ I don't lalov_ 
4, What 1a year blood prunn? I I ciou 't lalov -
S, What 1a your a:areise l ... el? _Active (at least l/2 hour every day) 
_Moderate (at least l/2 h erery other 
Mild (Weekanda only) 
=Mot aetire (lus than onc:a a veelc) 
day) 
6, Does any person 1o. your family have a history of heart problems, e.g., 
ehest pai.o., hypertoo.sioa, or haart attaelc: Yes_ No_ I cioa 't know_ 
7. Do yon ha'Ye almormal thyroid ftmc:tioa? Yes_ No_ I doa't lalov_ 
8. What is year Kuc:atiouel left!? 
___ Gracia sc:llool 
l!igh sthool === Uaciergraduate. studeat 
___ Uadergraduate Degrl!1! (B.A./Phann.D.) 
-
--Postgraduate degree (M.S./ Ph.D.) 
___ Not suted. 




10. Are you talcing preseriptioc 11111<11eatioa on ehronie basis? 
No_ Yes , l!ov """Y' l 2 3 4 s 
Please, Do not vr1 te below this line 
I!W· [g Ob: 
I R. F.: 
··~- ~/dL Gl!: N B I! 
Appendix c 
Cholesterol Awareness suryey (Pre-testl 
University of the Pacific 
School of Pharmacy 
Cholesterol Screening Project 
Please circle the appropriate answer according to your best knowledse. 
1. Have you ever heard of high blood cholesterol or hyperlipidemia? 




3. Have you been told by a doctor that your blood.cholesterol is high?Yes No 
4. High blood cholesterol is affected by dietary factors. True False 
5. Uoes high cholesterol lead to hardening of the blood vessels (arteries)? 
Yes No 
6. Uoes high blood cholesterol lead to heart attack ? Yes No 
7. Do you think that dietary action such as eating less saturated fats, egg, 
and lard would lower blood cholesterol? Yes No 
a. Uo you believe that reducing elevated blood cholesterol will have a large 
effect on heart disease? Yes No 
9. If you were found to have elevated blood.cholesterol, would you be willing 
to make dietary changes and/or ta~e medication to lower your blood level? 
___ Yes ___ No ___ I,am not sure 
10. Cigarette smoking by itself will increase your risk of heart attack? 













PATIENT EDUCATION MATERIAL 
USED IN THE STUDY 
Name of Publication Source 
Combat High Cholesterol citizens for Public 
Action on Cholesterol 
Coronary Risk Factors American Heart Association 
Exercise and Your Heart American Heart Association 
Your Heart and Dyslipidemia 
(It's more than High 
cholesterol) Park-Davis 
Elevated Cholesterol Merk Sharp & Oehme 
Lowering Your ·cholesterol 
(Diet information guidelines) Merk Sharp & Dohme 
Cholesterol, Questran and You Bristol Laboratories 
Appendix E 
Blood Cholesterol Progress Wallet Card 
University of the Pacif.ic: 
School of Pharmacy 
Cholesterol Screening Project 
Remember. 
Campus Pharmacy 
751 Brookside Road 
Stockton, CA 95211 
(209) 946-2411 
• Know your blood cholesterol level and what it means. 
• As a rule of thumb, a 1% reduction i.n blood cholesterol 
reduces the incidence of heart attacks by 2%. 
• Include lowfat milk/yogurt/cheese, fruits, vegetables, 
fish, and only lean meat in your diet 
• A void lard, butter, egg yolk.. animal organs/skin, ·and 









Test# 1 2 3 

























Preliminary Evaluation Sheet 
University of the Pacific 
School of Pharmacy 
Cholesterol Screening Project 
If you were found to have a high blood cholesterol level 
would you be willing to: 
1. Voluntarily modify your diet in an attempt to lower your 
elevated cholesterol by eating less saturated fatS and 
126 
cholesterol for a one month trial period. Yes No 
2. Repeat your blood cholesterol analysis twice by your 
pharmacist within a 4 month period (one and three months 
after this initial test) absolutely FREE. Yes No 
3. Receive appropriate educational material, a pharmacist's 
advice,. and answers to your questions on cholesterol. Yes No 
4.' Be referred to your family physician or a health center 
to establish the final diagnosis of your condition. Yes No 
5. Give authorization to your pharmacist to receive a copy 
of your blood lipid profile for follow-up purposes. Yes No 
6. Receive a certificate of participation in our project. Yes No 
Participant's Signature ------------- Date ----
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Appendix G 
Participant Interest in Future Blood Level Measurements 
From the following list, please circle the number 
of test(s) which you would use in the future if 
they were available in your community pharmacy: 





5 Uric Acid 
6 Serum Creatinine 
7 Blood Urea Nitrogen 
8 Liver Function Tests 
(GGT, SGOT, SGPT) 
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Appendix H 
Cholesterol Awareness Survey (Post-test) 
DaiYera~ty of t~e Pac~fic 
Sc~ool of ,.ar.acy 
Cholesterol Screeaiaa Project Pleaae circle tke appropriate aaaver: 













contains the hisheat amount 
c-Liver, beef d-Sea food 
(2 oz) (2 oz) 
of cholesterol? 
& fish 
Which of the 
a-2 % milk 
following contains 
b-Low fat yogurt 
the hi1kest amount of saturated fats? 
(1 cup) ( 8 0 z) 
Which of the following 
1• aaturate4 fat? 
a- popcorn (buttered) 
(2 oz) 
c-Coconut oil d-Shrimp,steamed 
(1 tbsp) (2 oz) 
contains lov cholesterol content but hiah 
b-Apple c-Coconut oil 
(one) (1 tbsp) 
Does high cholesterol lead to hardening of the 
d-Skim milk 
{1 cup) 
blood vessels (arteries)'? 
Yea lo 
6. Does high blood cholesterol lead to heart attack ? Yes lo 
7. Do you think that dietary action such as eating less saturated fats, egg, 
and lard would lower blood cholesterol? Yes lo 
8. Do you believe that reducing elevated blood cholesterol will have an effect 
on heart disease?. Yes Jlo 
9. Because of your elevated blood cholesterol, did you make dietary changes 
and/or take medication.to lover your blood cholesterol during this study? 
Yes J"o 
10. Did you consult with other health care provider (your physician, health 
center, or a dietitian to reduce your blood cholesterol as a result of the 
screening project~ 
•• I rl11 Yes: specify ---------
11. What is your attitude toward the idea of screening blood cholesterol in a 
community pharmacy done by a pharmacist~ 
a. I stroaslJ like it c. I doa't like it 
12. Is it a convenient service for you? Yes lo 
13. If blood cholesterol analysis were available in your community pharmacy, 
would you use this service in the future? Yes J"o 
14. Would you be willing to pay for this service if it were to be offered in 
your neighborhood pharmacy? 
•o Tea: If so, what would be a reasonable fee? 
$3 or less $5 $10 More than SlO 
Appendix I 
University of the Pacific 
School of Phannacy 
CERTIFICATE OF PARTICIPATION 
This certifies that 
has successfully participated in 
The Pharmacist's Cholesterol Screening/Awareness Project 
conducted at the School of Pharmacy. 
This is a recognition of the participant's effort to lower coronary artery 
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